<SEC-DOCUMENT>0000950123-11-093083.txt : 20111028
<SEC-HEADER>0000950123-11-093083.hdr.sgml : 20111028
<ACCEPTANCE-DATETIME>20111028172651
ACCESSION NUMBER:		0000950123-11-093083
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20111028
DATE AS OF CHANGE:		20111028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-170300
		FILM NUMBER:		111166159

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>f60024b5e424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
<TITLE>e424b5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">PROSPECTUS SUPPLEMENT
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed pursuant to Rule&nbsp;424(b)(5)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(To Prospectus dated November&nbsp;3, 2010)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Registration No.&nbsp;333-170300</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>$30,000,000 of Common Stock</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><IMG src="f60024b5f6002401.gif" alt="(STEMCELLS)">
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>STEMCELLS, INC.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should read this prospectus supplement and the accompanying prospectus carefully before
you invest. Both documents contain information you should consider carefully before making your
investment decision.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement relates to the issuance and sale of up to $30,000,000 of our common
stock from time to time through our sales agent, Cantor Fitzgerald &#038; Co. These sales, if any, will
be made pursuant to the terms of a sales agreement, as entered into on June&nbsp;5, 2009, between us and
the sales agent, which was filed with the Securities and Exchange Commission as an exhibit to our
report on Form 8-K dated October&nbsp;28, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock trades on the NASDAQ Global Market (NASDAQ)&nbsp;under the symbol &#147;STEM.&#148; Sales of
shares of our common stock under this prospectus supplement, if any, may be made by any method
deemed to be an &#147;at-the-market&#148; offering as defined in Rule&nbsp;415 under the Securities Act of 1933,
as amended, which includes sales made directly on the NASDAQ, the existing trading market for our
common stock, sales made to or through a market maker other than an exchange or otherwise, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to
such prevailing market prices, and/or any other matter permitted by law. The sales agent will make
all sales on a best efforts basis using commercially reasonable efforts consistent with its normal
trading and sales practices, on mutually agreed terms between the sales agent and us. There is no
arrangement for funds to be received in any escrow, trust or similar arrangement. On October&nbsp;27,
2011, the last reported sales price of our common stock on the NASDAQ was $2.00 per share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The compensation to the sales agent for sales of common stock sold pursuant to the sales
agreement will be an aggregate of 3% of the gross proceeds of the sales price of common stock sold.
The net proceeds from any sales under this prospectus supplement will be used as described under
&#147;Use of Proceeds.&#148; The proceeds that we receive from sales of our common stock will depend on the
number of shares actually sold and the offering price of such shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the sale of common stock on our behalf, the sales agent may be deemed to be
an &#147;underwriter&#148; within the meaning of the Securities Act of 1933, as amended, and the compensation
of such sales agent may be deemed to be underwriting commissions or discounts. We have agreed to
provide indemnification and contribution to the sales agent against certain liabilities, including
liabilities under the Securities Act of 1933, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<DIV style="width: 100%; border-bottom: 1px solid #000000; FONT-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>You
should read carefully and consider the &#147;Risk Factors&#148;
referenced on page S-6 of this
prospectus supplement and the risk factors described in other documents incorporated by reference
herein.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<DIV style="width: 100%; border-bottom: 1px solid #000000; FONT-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined that this prospectus supplement or the
accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f60024b5f6002402.gif" alt="(CANTOR)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The date of this prospectus is October&nbsp;28, 2011
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="F60024tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Prospectus Supplement</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024101">About this Prospectus Supplement</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024102">Prospectus Summary</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024103">Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024104">The Offering</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024105">Note Regarding Forward-Looking Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024106">Use of Proceeds</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024107">Plan of Distribution</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024108">Where You Can Find More Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024109">Incorporation of Certain Documents by Reference</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">S-11</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Prospectus</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prospectus Summary</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk factors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Note Regarding Forward-looking statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Use of proceeds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ratio of earnings to fixed charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Plan of distribution</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Description of Common Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Description of Preferred Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Description of Warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Description of Debt Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Legal matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Experts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Where you can find more information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Incorporation of certain documents by reference</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Unless the context requires otherwise, the words &#147;StemCells,&#148; &#147;we,&#148; &#147;company,&#148; &#147;us&#148; and &#147;our&#148; refer
to StemCells, Inc. and our directly and indirectly wholly-owned subsidiaries.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->S-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document consists of two parts. The first part is this prospectus supplement, which
describes the specific terms of this offering. The second part, the accompanying prospectus, gives
more general information, some of which may not apply to this offering. Generally, when we refer
only to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement may
add to, update or change information in the accompanying prospectus and the documents incorporated
by reference into this prospectus supplement or the accompanying prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If information in this prospectus supplement is inconsistent with the accompanying prospectus,
you should rely on this prospectus supplement. This prospectus supplement, the accompanying
prospectus and the documents incorporated into each by reference include important information
about us, the shares being offered and other information you should know before investing in our
common shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should rely only on this prospectus supplement, the accompanying prospectus and the
information incorporated or deemed to be incorporated by reference in this prospectus supplement
and the accompanying prospectus. We have not, and the sales agent has not, authorized anyone to
provide you with information that is in addition to, or different from, that contained or
incorporated by reference in this prospectus supplement and the accompanying prospectus. If anyone
provides you with different or inconsistent information, you should not rely on it. We are not, and
the sales agent is not, offering to sell securities in any jurisdiction where the offer or sale is
not permitted. You should not assume that the information contained or incorporated by reference in
this prospectus supplement or the accompanying prospectus is accurate as of any date other than as
of the date of this prospectus supplement or the accompanying prospectus, as the case may be, or in
the case of the documents incorporated by reference, the date of such documents regardless of the
time of delivery of this prospectus supplement and the accompanying prospectus or any sale of our
common shares. Our business, financial condition, liquidity, results of operations, and prospects
may have changed since those dates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All references in this prospectus to &#147;StemCells,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; mean
StemCells, Inc., including our directly and indirectly wholly-owned subsidiaries, unless we state
otherwise or the context otherwise requires.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024102"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROSPECTUS SUMMARY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The following is a summary of selected information contained elsewhere or incorporated by
reference in this prospectus. It does not contain all of the information that you should consider
before buying our securities. You should read this entire prospectus carefully, especially the
section entitled &#147;Risk Factors&#148; and the consolidated financial statements and the notes to the
consolidated financial statements incorporated by reference.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>The Company</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Business Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are engaged in researching, developing, and commercializing stem cell therapeutics and
enabling tools and technologies for stem cell-based research and drug discovery and development.
Our research and development (R&#038;D) programs are primarily focused on identifying and developing
potential cell-based therapeutics which can either restore or support organ function. In
particular, since we relocated our corporate headquarters to California in 1999, our R&#038;D efforts
have been directed at refining our methods for identifying, isolating, culturing, and purifying the
human neural stem cell and human liver engrafting cells (hLEC) and developing these as potential
cell-based therapeutics for the central nervous system (CNS)&nbsp;and the liver, respectively. In our
CNS Program, our HuCNS-SC<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> product candidate (purified human neural stem cells) is
currently in clinical development for spinal cord injury and Pelizeaus-Merzbacher Disease (PMD), a
myelination disorder in the brain. We are currently conducting a Phase I/II clinical trial in
Switzerland of our HuCNS-SC cells for the treatment of chronic spinal cord injury, and successfully
transplanted the first patient in this trial in September&nbsp;2011. In the United States, we completed
in February&nbsp;2011 patient accrual in our Phase I clinical trial in PMD. Following completion of the
trial in February&nbsp;2012, data from the trial is expected to be reported in early 2012. In addition,
we plan to submit in 2011 an IND to conduct a Phase I/II clinical trial in the dry form of
age-related macular degeneration. We previously completed a Phase I clinical trial in infantile and
late infantile neuronal ceroid lipofuscinosis (NCL, also known as Batten disease), and the data
from that trial showed that our HuCNS-SC cells were well tolerated and non-tumorigenic, and that
there was evidence of engraftment and long-term survival of the transplanted HuCNS-SC cells. In our
Liver Program, we are focused on identifying and developing liver cells as potential therapeutics
for a range of liver diseases. For a brief description of our significant therapeutic research and
development programs see Overview &#147;Research and Development Programs&#148; in the Business Section of
Part&nbsp;I, Item&nbsp;1 of our Form 10-K for the year ended December&nbsp;31, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are also engaged in developing and commercializing applications of our technologies to
enable research, which we believe represent current and nearer-term commercial opportunities. Our
portfolio of technologies includes cell technologies relating to embryonic stem cells, induced
pluripotent stem (iPS) cells, and tissue-derived (adult)&nbsp;stem cells; expertise and infrastructure
for providing cell-based assays for drug discovery; a cell culture products and antibody reagents
business; and an intellectual property portfolio with claims relevant to cell processing,
reprogramming and manipulation, as well as to gene targeting and insertion. Much of these enabling
technologies were acquired in April&nbsp;2009 as part of our acquisition of the operations of Stem Cell
Sciences Plc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not derived any revenue or cash flows from the sale or commercialization of any
products except for license revenue for certain of our patented technologies and sales of cell
culture products for use in research. As a result, we have incurred annual operating losses since
inception and expect to incur substantial operating losses in the future. Therefore, we are
dependent upon external financing from equity and debt offerings and revenue from collaborative
research arrangements with corporate sponsors to finance our operations. We have no such
collaborative research arrangements at this time and there can be no assurance that such financing
or partnering revenue will be available when needed or on terms acceptable to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before we can derive revenue or cash inflows from the commercialization of any of our
therapeutic product candidates, we will need to: (i)&nbsp;conduct substantial <I>in vitro </I>testing and
characterization of our proprietary cell types, (ii)&nbsp;undertake preclinical and clinical testing for
specific disease indications, (iii)&nbsp;develop, validate and scale-up manufacturing processes to
produce these cell-based therapeutics, and (iv)&nbsp;obtain required regulatory approvals. These steps
are risky, expensive and time consuming.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overall, we expect our R&#038;D expenses to be substantial and to increase for the foreseeable
future as we continue the development and clinical investigation of our current and future product
candidates. However, expenditures on R&#038;D programs are subject to many uncertainties, including
whether we develop our product
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">candidates with a partner or independently. We cannot forecast with any degree of certainty
which of our current product candidates will be subject to future collaboration, when such
collaboration agreements will be secured, if at all, and to what degree such arrangements would
affect our development plans and capital requirements. In addition, there are numerous factors
associated with the successful commercialization of any of our cell-based therapeutics, including
future trial design and regulatory requirements, many of which cannot be determined with accuracy
at this time given the stage of our development and the novel nature of stem cell technologies. The
regulatory pathways, both in the United States and internationally, are complex and fluid given the
novel and, in general, clinically unproven nature of stem cell technologies. At this time, due to
such uncertainties and inherent risks, we cannot estimate in a meaningful way the duration of, or
the costs to complete, our R&#038;D programs or whether, when or to what extent we will generate
revenues or cash inflows from the commercialization and sale of any of our therapeutic product
candidates. While we are currently focused on advancing each of our product development programs,
our future R&#038;D expenses will depend on the determinations we make as to the scientific and clinical
prospects of each product candidate, as well as our ongoing assessment of the regulatory
requirements and each product candidate&#146;s commercial potential.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given the early stage of development of our therapeutic product candidates, any estimates of
when we may be able to commercialize one or more of these products would not be meaningful.
Moreover, any estimate of the time and investment required to develop potential products based upon
our proprietary HuCNS-SC and hLEC technologies will change depending on the ultimate approach or
approaches we take to pursue them, the results of preclinical and clinical studies, and the content
and timing of decisions made by the FDA, Swissmedic and other regulatory authorities. There can be
no assurance that we will be able to develop any product successfully, or that we will be able to
recover our development costs, whether upon commercialization of a developed product or otherwise.
We cannot provide assurance that any of these programs will result in products that can be marketed
or marketed profitably. If certain of our development-stage programs do not result in commercially
viable products, our results of operations could be materially adversely affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The research markets served by our tools and technologies products are highly competitive,
complex and dynamic. Technological advances and scientific discoveries have accelerated the pace of
change in biological research, and stem cell technologies have been evolving particularly fast. We
compete mainly by focusing on specialty media and antibody reagent products and cell-based assays,
which are custom designed for use in stem cell-based research, where we believe our expertise,
intellectual property and reputation give us competitive advantage. We believe that, in this
particular market niche, our products and technologies offer customers specific advantages over
those offered by our competitors. We compete by offering innovative, quality-controlled products,
consistently made and designed to produce reproducible results. We continue to make investments in
research and development, quality management, quality improvement, and product innovation. We
cannot assure you that we will have sufficient resources to continue to make such investments. For
the three-month period ended September&nbsp;30, 2011, we generated revenues from the sale of specialty
cell culture products of approximately $182,000. There can be no assurance that we will be able to
continue to generate such revenues in the future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;30, 2011, we had cash, cash equivalents and marketable securities of
approximately $12.5&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Our Corporate Information</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are incorporated in Delaware. Our principal executive offices are located at 7707 Gateway
Blvd., Suite&nbsp;140, Newark, California 94560 and our telephone number is (510)&nbsp;456-4000. Our website
is located at www.stemcellsinc.com. We have not incorporated by reference into this prospectus
supplement or the accompanying prospectus the information in, or that can be accessed through, our
website, and you should not consider it to be a part of this prospectus supplement or the
accompanying prospectus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024103"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RISK FACTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>You should consider the &#147;Risk Factors&#148; included and incorporated by reference in this
prospectus and any applicable prospectus supplement, including the risk factors incorporated by
reference from our most recent Annual Report on </I><I>Form 10-K</I><I> for the fiscal year ended December&nbsp;31,
2010, filed with the SEC on March&nbsp;11, 2011, as updated by our Quarterly Reports on </I><I>Form 10-Q</I><I> and
our other filings with the SEC pursuant to Sections&nbsp;</I><I>13(a)</I><I>, </I><I>13(c)</I><I>, 14 or </I><I>15(d)</I><I> of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), filed after such annual report. The risks
and uncertainties we describe are not the only ones facing us. Additional risks not presently known
to us, or that we currently deem immaterial, may also impair our business operations. If any of
these risks were to occur, our business, financial condition, or results of operations would likely
suffer. In that event, the trading price of our common stock could decline, and you could lose all
or part of your investment.</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024104"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>The Offering</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The following summary contains basic information about our common stock and the offering and
is not intended to be complete. It does not contain all the information that may be important to
you. For a more complete understanding of our common stock, you should read the section of the
accompanying prospectus entitled &#147;Description of Common Stock.&#148;</I>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Issuer</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">StemCells, Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Common stock offered</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Up to $30,000,000 of common stock</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Manner of offering</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;At-the-market&#148; offering that may be made from time
to time through our sales agent, Cantor Fitzgerald &#038;
Co. See &#147;Plan of Distribution&#148; on page 10.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Use of proceeds</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">We intend to use net proceeds of this offering for
general corporate purposes, including working
capital, product development and capital
expenditures, as well as acquisitions and other
strategic purposes.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Risk factors</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Your investment in our common shares involves
substantial risks. You should consider the &#147;Risk
Factors&#148; included and incorporated by reference in
this prospectus supplement and the accompanying
prospectus, including the risk factors incorporated
by reference from our filings with the United States
Securities and Exchange Commission (the &#147;SEC&#148;).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>NASDAQ ticker symbol</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">STEM</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->S-7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024105"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOTE REGARDING FORWARD-LOOKING STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement, the accompanying prospectus and the documents incorporated in this
prospectus supplement contain forward looking statements that involve substantial risks and
uncertainties. Such statements include, without limitation, all statements as to expectation or
belief and statements as to our future results of operations; the progress of our research, product
development and clinical programs; the need for, and timing of, additional capital and capital
expenditures; partnering prospects; costs of manufacture of products; the protection of, and the
need for, additional intellectual property rights; effects of regulations; the need for additional
facilities; and potential market opportunities. Our actual results may vary materially from those
contained in such forward-looking statements because of risks to which we are subject, including
the fact that additional trials will be required to confirm the safety and demonstrate the efficacy
of our HuCNS-SC cells for the treatment of spinal cord injury, Pelizeaus-Merzbacher disease (PMD),
age-related macular degeneration or any other disease; uncertainty as to whether the U.S. Food and
Drug Administration (FDA), Swissmedic, or other regulatory authorities will permit us to proceed
with clinical testing of proposed products despite the novel and unproven nature of our
technologies; the risk that our clinical trials or studies could be substantially delayed beyond
their expected dates or cause us to incur substantial unanticipated costs; uncertainties in our
ability to obtain the capital resources needed to continue our current research and development
operations and to conduct the research, preclinical development and clinical trials necessary for
regulatory approvals; the uncertainty regarding our ability to obtain a corporate partner or
partners, if needed, to support the development and commercialization of our potential cell-based
therapeutics products; the uncertainty regarding the outcome of our clinical trials or studies we
may conduct in the future; the uncertainty regarding the validity and enforceability of our issued
patents; the risk that we may not be able to manufacture additional master and working cell banks
when needed; the uncertainty whether any products that may be generated in our cell-based
therapeutics programs will prove clinically safe and effective; the uncertainty whether we will
achieve significant revenue from product sales or become profitable; obsolescence of our
technologies; competition from third parties; intellectual property rights of third parties;
litigation risks; and other risks to which we are subject. All forward-looking statements
attributable to us or to persons acting on our behalf are expressly qualified in their entirety by
the cautionary statements and risk factors set forth in &#147;Risk Factors&#148; in Part&nbsp;I, Item&nbsp;1A of our
Form 10-K for the year ended December&nbsp;31, 2010.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>USE OF PROCEEDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the maximum net proceeds from the sale of all shares of common stock sold
pursuant to the sales agreement with Cantor Fitzgerald &#038; Co to be $28,900,000, after deducting
sales commissions and the estimated expenses. We intend to use the net proceeds from these
offerings for general corporate purposes, including working capital, product development and
capital expenditures, as well as acquisitions and other strategic purposes. As of October&nbsp;27,
2011, approximately $23,900,000 in shares of our common stock remained available for sales pursuant
to the sales agreement with Cantor Fitzgerald &#038; Co.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024107"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PLAN OF DISTRIBUTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into an at-the-market issuance sales agreement, dated as of June&nbsp;5, 2009 with
Cantor Fitzgerald &#038; Co. (the &#147;sales agent&#148;), under which we may sell an aggregate of $30,000,000 of
our common stock from time to time through the sales agent. The sales agent may sell the
common stock by any method that is deemed to be an &#147;at-the-market&#148; offering as defined in Rule&nbsp;415
of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), including sales made directly on
the NASDAQ Global Market or on any other existing trading market for the common stock. The sales
agent may also sell the common stock in privately negotiated transactions, subject to our prior
approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each time that we wish to issue and sell common stock under the sales agreement, we will agree
with the sales agent on the number of shares to be issued, the dates on which such sales are
anticipated to be made and any minimum price below which sales may not be made. Once we have so
instructed the sales agent, the sales agent has agreed to use its commercially reasonable efforts
consistent with its normal trading and sales practices to sell such shares up to the amount
specified on such terms. The settlement between us and the sales agent of our common stock is
generally anticipated to occur on the third business day following the date on which the sale was
made. The obligation of the sales agent under the sales agreement to sell our common stock is
subject to a number of conditions that we must meet.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay the sales agent a total commission equal to an aggregate of 3% of the gross
proceeds we receive from the sales of our common stock. Because there is no minimum offering amount
required as a condition to closing this offering, the actual total public offering amount,
commissions and proceeds to us, if any, are not determinable at this time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the sale of our common stock contemplated in this prospectus supplement,
the sales agent may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and
the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts.
We have agreed to indemnify the sales agent against certain civil liabilities, including
liabilities under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of our common stock as contemplated in this prospectus supplement will be settled
through the facilities of The Depository Trust Company or by such other means as we and the sales
agent may agree upon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The offering of our common stock pursuant to the sales agreement will terminate on the
earliest of (1)&nbsp;the sale of all of our common stock subject to the sales agreement, or (2)
termination of the sales agreement by us or the sales agent. The sales agent may terminate the
sales agreement at any time in certain circumstances, including the occurrence of a material
adverse change that, in the sales agent&#146;s reasonable judgment, may impair its ability to sell the
common stock, our failure to satisfy any condition under the sales agreement or a suspension or
limitation of trading of our common stock on the NASDAQ Global Market. We and the sales agent may
each terminate the sales agreement at any time upon 10&nbsp;days prior notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This summary of the material provisions of the sales agreement does not purport to be a
complete statement of its terms and conditions. A copy of the sales agreement is filed with the SEC
and incorporated by reference into the registration statement of which this prospectus supplement
forms a part. See &#147;Where You Can Find More Information&#148; below.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024108"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WHERE YOU CAN FIND MORE INFORMATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly, and special reports, proxy statements, and other information with
the SEC. These documents are on file with the SEC under file number 000-19871. You may read and
copy any document we file at the SEC&#146;s public reference room at 100 F Street, N.E., Washington,
D.C., 20549. You can request copies of these documents by contacting the SEC and paying a fee for
the copying cost. Please call the SEC at 1-800-SEC-0330 for further information on the public
reference room. Our SEC filings are also available to the public from the SEC&#146;s website at
www.sec.gov.
</DIV>
<DIV align="left">
<A name="F60024109"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement and the accompanying prospectus are part of a registration
statement on Form S-3 filed by us with the SEC. This prospectus supplement and the accompanying
prospectus do not contain all of the information set forth in the registration statement, certain
parts of which are omitted in accordance with the rules and regulations of the SEC. Statements
contained in this prospectus supplement, the accompanying prospectus or the documents incorporated
by reference into this prospectus supplement or the accompanying prospectus as to the contents of
any contract or other document referred to are not necessarily complete and in each instance
reference is made to the copy of that contract or other document filed with the SEC. For further
information about us and the securities offered by this prospectus supplement, we refer you to the
registration statement and its exhibits and schedules which may be obtained as described herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to &#147;incorporate by reference&#148; the information contained in documents that we
file with them, which means that we can disclose important information to you by referring you to
those documents. The information incorporated by reference is considered to be part of this
prospectus supplement and the accompanying prospectus, and information in documents that we file
later with the SEC will automatically update and supersede information in this prospectus
supplement and the accompanying prospectus. We incorporate by reference the documents listed below
into this prospectus supplement, and any future filings made by us with the SEC under Section
13(a), 13(c), 14 or 15(d) of the Exchange Act until the offering of all the securities by this
prospectus supplement is completed, including all filings made after the date of this prospectus
supplement. We hereby incorporate by reference the documents listed below:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our Annual Report on Form 10-K for the
fiscal year ended December&nbsp;31, 2010 as
filed on March&nbsp;3, 2011, as amended April
29, 2011;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2011 as filed on May&nbsp;10, 2011;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2011 as filed on August&nbsp;5, 2011;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our Current Reports on Form 8-K filed
on January&nbsp;6, 2011, January&nbsp;7, 2011,
January&nbsp;11, 2011, February&nbsp;18, 2011, March
4, 2011, March&nbsp;15, 2011 (excluding the
information furnished pursuant to Item
7.01, including the exhibit furnished
therewith), May&nbsp;4, 2011 (the information
presented in Item&nbsp;2.05 only), July&nbsp;6, 2011,
July&nbsp;18, 2011, July&nbsp;28, 2011 (the
information presented in Item&nbsp;9.01 only),
and September&nbsp;22, 2011; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the description of our common stock
contained in our registration statements on
Form 8-A filed August&nbsp;3, 1998, under the
Exchange Act, including any amendment or
report filed for the purpose of updating
such description.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will provide each person to whom this prospectus supplement is delivered a copy of all
of the information that has been incorporated by reference in this prospectus supplement or the
accompanying prospectus but not delivered with this prospectus supplement and the accompanying
prospectus. You may obtain copies of these filings, at no cost, through the &#147;Investor Relations&#148;
section of our website (www.stemcellsinc.com), and you may request copies of these filings, at no
cost, by writing or telephoning us at:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">StemCells, Inc.<BR>
7707 Gateway Blvd., Suite&nbsp;140<BR>
Newark, CA 94560
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Attention: Investor Relations<BR>
Phone: (510)&nbsp;456-4000<BR>
e-mail: <u>irpr@stemcellsinc.com</u>

</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->S-11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">PROSPECTUS
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" style="color: #FF0000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">$100,000,000</DIV>


<DIV align="center" style="font-size: 18pt; margin-top: 18pt"><B>STEMCELLS, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 12pt; margin-top: 6pt">Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Debt Securities<BR>
<B>&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may offer to the public, from time to time, in one or more series or issuances:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>shares of our common stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>shares of our preferred stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>warrants to purchase shares of our common stock, preferred stock and/or debt securities;
or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>debt securities consisting of debentures, notes or other evidences of indebtedness.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus provides a general description of the securities we may offer. Each time we
sell securities, we will provide specific terms of the securities offered in a supplement to this
prospectus. The prospectus supplement may also add, update or change information contained in this
prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied
by the applicable prospectus supplement. You should read both this prospectus and any prospectus
supplement together with additional information described under the heading &#147;Where You Can Find
More Information&#148; before you make your investment decision.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will sell these securities directly to our stockholders or to purchasers or through agents
on our behalf or through underwriters or dealers as designated from time to time. If any agents or
underwriters are involved in the sale of any of these securities, the applicable prospectus
supplement will provide the names of the agents or underwriters and any applicable fees,
commissions or discounts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is traded on the Nasdaq Global Market under the symbol &#147;STEM.&#148; On
November&nbsp;1, 2010, the closing price of our common stock was $0.88.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Investing in our securities involves certain risks. Please carefully consider &#147;Risk
Factors&#148; on page 5 and other information included and incorporated by reference in this
prospectus, and in any applicable prospectus supplement, for a discussion of the factors you should
consider carefully before deciding to purchase our securities</B>.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the accuracy or adequacy of this
prospectus. Any representation to the contrary is a criminal offense.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The
date of this prospectus is November 16, 2010
</DIV>








<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="F60024tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024151">Prospectus Summary</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024152">Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024153">Note Regarding Forward-Looking Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024154">Use of Proceeds</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024155">Ratio of Earnings to Fixed Charges</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024156">Plan of Distribution</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024157">Description of Common Stock</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024158">Description of Preferred Stock</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024159">Description of Warrants</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024160">Description of Debt Securities</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024161">Legal Matters</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024162">Experts</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024163">Where You Can Find More Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#F60024164">Incorporation of Certain Documents by Reference</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">18</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) utilizing a &#147;shelf&#148; registration process. Under this shelf process,
we may sell different types of securities described in this prospectus in one or more offerings.
This prospectus provides you with a general description of the securities we may offer. Each time
we offer securities, we will provide a prospectus supplement and attach it to this prospectus. The
prospectus supplement will contain specific information about the nature of the persons offering
securities and the terms of the securities being offered at that time. The prospectus supplement
may also add, update or change information contained in this prospectus. You should read both this
prospectus and any prospectus supplement, including all documents incorporated herein by reference,
together with additional information described under the headings &#147;Where You Can Find More
Information&#148; and &#147;Incorporation of Certain Documents By Reference.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus does not contain all of the information that is in the registration statement.
We omitted certain parts of the registration statement from this prospectus as permitted by the
SEC. We refer you to the registration statement and its exhibits for additional information about
us and the securities that may be sold under this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All references in this prospectus to &#147;StemCells,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; mean
StemCells, Inc. and its subsidiaries unless we state otherwise or the context otherwise requires.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should rely only on the information contained or incorporated by reference in this
prospectus. We have not authorized anyone to provide you with different information. If anyone
provides you with different or inconsistent
information, you should not rely on it. We are not making an offer to sell these
securities in any jurisdiction where the offer is not permitted. The information contained in this
prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery
of this prospectus or the time of any sale of our securities. Our business, financial condition,
results of operations, and prospects may have changed since such date.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="F60024151"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROSPECTUS SUPPLEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The following is a summary of selected information contained elsewhere or incorporated by
reference in this prospectus. It does not contain all of the information that you should consider
before buying our securities. You should read this entire prospectus carefully, especially the
section entitled &#147;Risk Factors&#148; and the consolidated financial statements and the notes to the
consolidated financial statements incorporated by reference.</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Our Company</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are engaged in researching, developing, and commercializing stem cell therapeutics and
technologies for stem cell-based research, drug discovery and development. Our research and
development efforts primarily support our therapeutic product programs, where we are engaged in
identifying and developing potential cell-based therapeutics which can either restore or support
organ function. In particular, since we relocated our corporate headquarters to California in 1999,
our efforts have been directed at refining our methods for identifying, isolating, culturing, and
purifying the human neural stem cell and human liver engrafting cells (hLEC) and developing these
as potential cell-based therapeutics for the central nervous system (CNS)&nbsp;and the liver,
respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In our CNS Program, our HuCNS-SC<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> product candidate (purified human neural stem
cells) is currently in clinical development for two neurodegenerative brain disorders, and our goal
is to initiate clinical testing of our HuCNS-SC cells for spinal cord injury in 2011 and for
degenerative retinal disorders in 2012. We have completed a six patient Phase I clinical trial in
infantile and late infantile neuronal ceroid lipofuscinosis (NCL), a lysomal storage disorder often
referred to as Batten disease. The data from this trial showed that the HuCNS-SC cells were well
tolerated, and there was evidence of engraftment and long-term survival of the HuCNS-SC cells. In
October&nbsp;2010, we initiated a second clinical trial in NCL to further assess the safety of HuCNS-SC
cells and to examine their ability to affect the progression of the disease. We are also currently
conducting a Phase I clinical trial to assess the safety and preliminary effectiveness of HuCNS-SC
cells as a treatment for Pelizeaus-Merzbacher Disease (PMD), a myelination disorder in the brain.
Two of the four planned patients for this trial have been enrolled and transplanted with our
HuCNS-SC cells, and we anticipate completing enrollment in early 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In our Liver Program, we have identified a subset of our human liver engrafting cells which we
believe may be a candidate for product development, and we are working to purify and characterize
this subset. We have also conducted research on several other cell types and in other areas,
which could lead to other possible product candidates, process improvements or further research
activities. For a brief description of our significant therapeutic research and development
programs, see &#147;Business &#151; Overview &#151; Cellular Medicine Programs&#148; in Part&nbsp;I, Item&nbsp;1 included in
our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2009 (the 2009 10-K).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are also engaged in developing and commercializing applications of our technologies to
enable stem cell-based research, which we believe represent nearer-term commercial opportunities.
Our portfolio of enabling technologies includes cell technologies relating to embryonic stem cells,
induced pluripotent stem (iPS) cells, and tissue-derived (adult)&nbsp;stem cells; expertise and
infrastructure for providing cell-based assays for drug discovery; a cell culture products
business; and an intellectual property portfolio with claims relevant to cell processing,
reprogramming and manipulation, as well as to gene targeting and insertion. Many of our enabling
technologies were acquired in April&nbsp;2009 as part of our acquisition of the operations of Stem Cell
Sciences Plc. For a brief description of our significant enabling technologies programs, see
&#147;Business &#151; Overview &#151; Enabling Technologies Programs&#148; in Part&nbsp;I, Item&nbsp;1 included in our 2009
10-K.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our principal executive offices are located at StemCells, Inc., 3155 Porter Drive, Palo Alto,
CA 94304 and our phone number is (650)&nbsp;475-3100.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024152"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RISK FACTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>You should consider the &#147;Risk Factors&#148; included and incorporated by reference in this
prospectus and any applicable prospectus supplement, including the risk factors incorporated by
reference from our most recent Annual Report on </I><I>Form 10-K</I><I> for this fiscal year ended December&nbsp;31,
2009, filed with the SEC on March&nbsp;11, 2010, as updated by our Quarterly Reports on </I><I>Form 10-Q</I><I> and
our other filings with the SEC pursuant to Sections&nbsp;</I><I>13(a)</I><I>, </I><I>13(c)</I><I>, 14 or </I><I>15(d)</I><I> of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) filed after such annual report. The risks
and uncertainties we describe are not the only ones facing us. Additional risks not presently known
to us, or that we currently deem immaterial, may also impair our business operations. If any of
these risks were to occur, our business, financial condition, or results of operations would likely
suffer. In that event, the trading price of our common stock could decline, and you could lose all
or part of your investment.</I>
</DIV>
<DIV align="left">
<A name="F60024153"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOTE REGARDING FORWARD-LOOKING STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus and the documents incorporated in this prospectus by reference may contain
&#147;forward-looking statements&#148;. Except for strictly historical information contained herein, matters
discussed in this report constitute forward-looking statements. Generally, these statements may be
identified by the use of forward-looking words or phrases such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;look forward,&#148; &#147;may,&#148; &#147;planned,&#148; &#147;potential,&#148; &#147;should,&#148; &#147;will,&#148;
and &#147;would,&#148; and similar terms. These forward-looking statements reflect our current expectations
and are based upon currently available data. The Private Securities Litigation Reform Act of 1995
provides a &#147;safe harbor&#148; for such forward-looking statements. In order to comply with the terms of
the safe harbor, we note that a variety of factors could cause actual results and experience to
differ materially from the anticipated results or other expectations expressed in the
forward-looking statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such statements include, without limitation, all statements as to expectation or belief and
statements as to our future results of operations; the progress of our research, product
development and clinical programs; the need for, and timing of, additional capital and capital
expenditures; partnering prospects; costs of manufacture of products; the protection of, and the
need for, additional intellectual property rights; effects of regulations; the need for additional
facilities; and potential market opportunities. Our actual results may vary materially from those
contained in such forward-looking statements because of risks to which we are subject, including
uncertainty as to whether the U.S. Food and Drug Administration (FDA)&nbsp;or other regulatory
authorities will permit us to proceed or continue with clinical testing of proposed products despite the novel
and unproven nature of our technologies; the risk that our initial clinical trial and any other
clinical trials or studies could be substantially delayed beyond their expected dates or cause us
to incur substantial unanticipated costs; uncertainties in our ability to obtain the capital
resources needed to continue our current research and development operations and to conduct the
research, preclinical development and clinical trials necessary for regulatory approvals; the
uncertainty regarding our ability to obtain a corporate partner or partners, if needed, to support
the development and commercialization of our potential cell-based therapeutics products; the
uncertainty about the design of current and future clinical trials and whether we will receive the
necessary support of a clinical trial site and its institutional review board to pursue current and
future clinical trials in NCL, PMD or in proposed therapies for other diseases or conditions; the
uncertainty regarding the outcome of our proposed clinical trial in NCL and any other clinical
trials or studies we may conduct in the future; the uncertainty regarding the validity and
enforceability of our issued patents; the uncertainty whether any products that may be generated in
our cell-based therapeutics programs will prove clinically safe and effective; the uncertainty
regarding our ability to commercialize a therapeutic product and its ability to successfully
compete with other products on the market; the uncertainty whether we will achieve revenue from
product sales or become profitable; uncertainties regarding our obligations with respect to our
former encapsulated cell therapy facilities in Rhode Island; obsolescence of our technologies;
competition from third parties; intellectual property rights of third parties; litigation risks;
and other risks to which we are subject. All forward-looking statements attributable to us or to
persons acting on our behalf are expressly qualified in their entirety by the cautionary statements
and risk factors set forth in &#147;Risk Factors&#148; in this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The forward-looking statements included in this prospectus represent our estimates as of the
date of this prospectus. We specifically disclaim any obligation to update these forward-looking
statements in the future. These forward-looking statements should not be relied upon as
representing our estimates or views as of any date subsequent to the date of this prospectus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024154"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>USE OF PROCEEDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the applicable prospectus supplement, we intend to use the net
proceeds from the sale of the securities covered by this prospectus for general corporate purposes,
which may include working capital, capital expenditures, research and development expenditures,
clinical trial expenditures, acquisitions of new technologies or businesses, and investments.
Additional information on the use of net proceeds from the sale of securities covered by this
prospectus may be set forth in the prospectus supplement relating to the specific offering.
</DIV>
<DIV align="left">
<A name="F60024155"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RATIO OF EARNINGS TO FIXED CHARGES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our earnings are inadequate to cover fixed charges. The following table sets forth the dollar
amount of the coverage. We have not included a ratio of earnings to combined fixed charges and
preferred stock dividends because we do not have any preferred stock outstanding.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Nine</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Months</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Ended</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>September</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="19" style="border-bottom: 1px solid #ffffff"><B>Year Ended December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #ffffff"><B>30, 2010</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #ffffff"><B>2005</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #ffffff"><B>2006</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #ffffff"><B>2007</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #ffffff"><B>2008</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #ffffff"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="23"><B>(in thousands)</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ratio of earnings
to fixed charges
(1)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficiency of
earnings available
to cover fixed
charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(13,726</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(20,927</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(27,107</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(31,307</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(29,156</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">(18,110</TD>
    <TD align="left">)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>In each of the periods presented, our earnings were insufficient to cover fixed charges and
accordingly ratios are not presented.</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left">
<A name="F60024156"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PLAN OF DISTRIBUTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell securities in any of the ways described below, including any combination thereof:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to or through underwriters or dealers;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>through one or more agents; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>directly to purchasers or to a single purchaser.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The distribution of the securities may be effected from time to time in one or more
transactions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at a fixed price, or prices, which may be changed from time to time;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at market prices prevailing at the time of sale;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at prices related to such prevailing market prices; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at negotiated prices.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each prospectus supplement will describe the method of distribution of the securities and any
applicable restrictions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The prospectus supplement with respect to the securities of a particular series will describe
the terms of the offering of the securities, including the following:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the name or names of any underwriters, dealers or agents and the amounts of
securities underwritten or purchased by each of them;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the initial public offering price of the securities and the proceeds to us and
any discounts, commissions or concessions allowed or reallowed or paid to dealers;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any securities exchanges on which the securities may be listed.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any initial public offering price and any discounts or concessions allowed or reallowed or
paid to dealers may be changed from time to time. In no event will any underwriter or dealer
receive fees, commissions and markups, which, in the aggregate, would exceed eight percent of the
price of the securities being registered.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only the agents or underwriters named in the prospectus supplement are agents or underwriters
in connection with the securities being offered.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may authorize underwriters, dealers or other persons acting as our agents to solicit offers
by certain institutions to purchase securities from us pursuant to delayed delivery contracts
providing for payment and delivery on the date stated in the prospectus supplement. Each contract
will be for an amount not less than, and the aggregate amount of securities sold pursuant to such
contracts shall not be less nor more than, the respective amounts stated in the prospectus
supplement. Institutions with whom the contracts, when authorized, may be made include commercial
and savings banks, insurance companies, pension funds, investment companies, educational and
charitable institutions and other institutions, but shall in all cases be subject to our approval.
Delayed delivery contracts will be subject only to those conditions set forth in the prospectus
supplement, and the prospectus supplement will set forth any commissions we pay for solicitation of
these contracts.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agents, underwriters and other third parties described above may be entitled to
indemnification by us against certain civil liabilities, including liabilities under the Securities
Act, or to contribution with respect to payments which the agents or underwriters may be required
to make in respect thereof. Agents, underwriters and such other third parties may be customers of,
engage in transactions with, or perform services for us in the ordinary course of business.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One or more firms, referred to as &#147;remarketing firms,&#148; may also offer or sell the securities,
if the prospectus supplement so indicates, in connection with a remarketing arrangement upon their
purchase. Remarketing firms will act as principals for their own accounts or as our agents. These
remarketing firms will offer or sell the securities in accordance with the terms of the securities.
The prospectus supplement will identify any remarketing firm and describe the terms of its
agreement, if any, with us and the remarketing firm&#146;s compensation. Remarketing firms may be
deemed to be underwriters in connection with the securities they remarket. Remarketing firms may
be entitled under agreements that may be entered into with us to indemnification by us against
certain civil liabilities, including liabilities under the Securities Act, and may be customers of,
engage in transactions with or perform services for us in the ordinary course of business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of the underwriters may use this prospectus and the accompanying prospectus supplement
for offers and sales related to market-making transactions in the securities. These underwriters
may act as principal or agent in these transactions, and the sales will be made at prices related
to prevailing market prices at the time of sale.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities may be new issues of securities and may have no established trading market. The
securities may or may not be listed on a national securities exchange. Underwriters may make a
market in these securities, but will not be obligated to do so and may discontinue any market
making at any time without notice. We can make no assurance as to the liquidity of, or the
existence of trading markets for, any of the securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain persons participating in this offering may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids in accordance with rules and regulations
under the Exchange Act. Overallotment involves sales in excess of the offering size, which create
a short position. Stabilizing transactions permit bids to purchase the underlying security so long
as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve
purchases of the securities in the open market after the distribution is completed to cover short
positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when
the securities originally sold by the dealer are purchased in a covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would
otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<A name="F60024157"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DESCRIPTION OF COMMON STOCK</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary of the terms of our common stock is subject to and qualified in its
entirety by reference to our charter and by-laws, copies of which are on file with the SEC as
exhibits to previous SEC filings. Please refer to &#147;Where You Can Find More Information&#148; below for
directions on obtaining these documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have authority to issue 250,000,000 shares of common stock. As of November 1, 2010, we
had 127,029,870 shares of common stock outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>General</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of common stock are entitled to one vote per share on matters on which our
stockholders vote. There are no cumulative voting rights. Holders of common stock are entitled to
receive dividends, if declared by our board of directors, out of funds that we may legally use to
pay dividends. If we liquidate or dissolve, holders of common stock are entitled to share ratably
in our assets once our debts and any liquidation preference owed to any then-outstanding preferred
stockholders are paid. Our certificate of incorporation does not provide the common stock with any
redemption, conversion or preemptive rights. All shares of common stock that are outstanding as of
the date of this prospectus and, upon issuance and sale, all shares we are offering by this
prospectus, will be fully-paid and nonassessable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Transfer Agent and Registrar</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Nasdaq Global Market</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed for quotation on the Nasdaq Global Market under the symbol &#147;STEM.&#148;
</DIV>
<DIV align="left">
<A name="F60024158"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DESCRIPTION OF PREFERRED STOCK</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have authority to issue 1,000,000 shares of undesignated preferred stock. As of
November 1, 2010, no shares of our preferred stock were outstanding. The following summary of certain
provisions of our preferred stock does not purport to be complete. You should refer to our restated
certificate of incorporation and our amended and restated by-laws, both of which are included as
exhibits to the registration statement we have filed with the SEC in connection with this offering.
The summary below is also qualified by provisions of applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors is authorized, without stockholder approval, from time to time, to
issue shares of preferred stock in series and may, at the time of issuance, subject to Delaware law
and our charter and by-laws, determine the rights, preferences and limitations of each series,
including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction
of any dividend preferences of outstanding shares of preferred stock would reduce the amount of
funds available for the payment of dividends on shares of our common stock. Holders of shares of
preferred stock may be entitled to receive a preference payment in the event of any liquidation,
dissolution or winding-up of our company before any payment is made to the holders of shares of our
common stock. In some circumstances, the issuance of shares of preferred stock may render more
difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control
by a holder of a large block of our securities or the removal of incumbent management. Upon the
affirmative vote of our board of directors, without stockholder approval, we may issue shares of
preferred stock with voting and conversion rights which could adversely affect the holders of
shares of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we offer a specific series of preferred stock under this prospectus, we will describe the
terms of the preferred stock in the prospectus supplement for such offering and will file a copy of
the certificate establishing the terms of the preferred stock with the SEC. To the extent required,
this description will include:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the title and stated value;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the number of shares offered, the liquidation preference per share and the purchase
price;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for
such dividends;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether dividends will be cumulative or non-cumulative and, if cumulative, the date from
which dividends will accumulate;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the procedures for any auction and remarketing, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the provisions for a sinking fund, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the provisions for redemption, if applicable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any listing of the preferred stock on any securities exchange or market;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether the preferred stock will be convertible into our common stock, and, if
applicable, the conversion price (or how it will be calculated) and conversion period;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether the preferred stock will be exchangeable into debt securities, and, if
applicable, the exchange price (or how it will be calculated) and exchange period;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>voting rights, if any, of the preferred stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a discussion of any material and/or special U.S. federal income tax considerations
applicable to the preferred stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the relative ranking and preferences of the preferred stock as to dividend rights and
rights upon liquidation, dissolution or winding up of the affairs of StemCells, Inc.; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any material limitations on issuance of any class or series of preferred stock ranking
senior to or on a parity with the series of preferred stock as to dividend rights and
rights upon liquidation, dissolution or winding up of StemCells, Inc.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preferred stock offered by this prospectus will, when issued, be fully paid and
nonassessable and will not have, or be subject to, any preemptive or similar rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Transfer Agent and Registrar</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for any series or class of preferred stock will be set forth
in the applicable prospectus supplement.
</DIV>

<DIV align="left">
<A name="F60024159"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DESCRIPTION OF WARRANTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue warrants to purchase shares of our common stock, preferred stock and/or debt
securities in one or more series together with other securities or separately, as described in the
applicable prospectus supplement. Below is a description of certain general terms and provisions of
the warrants that we may offer. Particular terms of the warrants will be described in the warrant
agreements and the prospectus supplement to the warrants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The applicable prospectus supplement will contain, where applicable, the following terms of,
and other information relating to, the warrants:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the specific designation and aggregate number of, and the price at which we will issue,
the warrants;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the currency or currency units in which the offering price, if any, and the exercise
price are payable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the designation, amount and terms of the securities purchasable upon exercise of the
warrants;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if applicable, the exercise price for shares of our common stock and the number of
shares of common stock to be received upon exercise of the warrants;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if applicable, the exercise price for shares of our preferred stock, the number of
shares of preferred stock to be received upon exercise, and a description of that series of
our preferred stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if applicable, the exercise price for our debt securities, the amount of debt securities
to be received upon exercise, and a description of that series of debt securities;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the date on which the right to exercise the warrants will begin and the date on which
that right will expire or, if you may not continuously exercise the warrants throughout
that period, the specific date or dates on which you may exercise the warrants;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether the warrants will be issued in fully registered form or bearer form, in
definitive or global form or in any combination of these forms, although, in any case, the
form of a warrant included in a unit will correspond to the form of the unit and of any
security included in that unit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any applicable material U.S. federal income tax consequences;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the identity of the warrant agent for the warrants and of any other depositaries,
execution or paying agents, transfer agents, registrars or other agents;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the proposed listing, if any, of the warrants or any securities purchasable upon
exercise of the warrants on any securities exchange;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if applicable, the date from and after which the warrants and the common stock,
preferred stock and/or debt securities will be separately transferable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if applicable, the minimum or maximum amount of the warrants that may be exercised at
any one time;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information with respect to book-entry procedures, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the anti-dilution provisions of the warrants, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any redemption or call provisions;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether the warrants are to be sold separately or with other securities as parts of
units; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any additional terms of the warrants, including terms, procedures and limitations
relating to the exchange and exercise of the warrants.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Transfer Agent and Registrar</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for any warrants will be set forth in the applicable
prospectus supplement.
</DIV>
<DIV align="left">
<A name="F60024160"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DESCRIPTION OF DEBT SECURITIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will issue the debt securities offered by this prospectus and any accompanying prospectus
supplement under an indenture to be entered into between us and the trustee identified in the
applicable prospectus supplement. The terms of the debt securities will include those stated in the
indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as
in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit
to the registration statement in which this prospectus is included. The indenture will be subject
to and governed by the terms of the Trust Indenture Act of 1939.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may offer under this prospectus up to an aggregate principal amount of $100,000,000 in
debt securities; or if debt securities are issued at a discount, or in a foreign currency, foreign
currency units or composite currency, the principal amount as may be sold for an initial public
offering price of up to $100,000,000. Unless otherwise specified in the applicable prospectus
supplement, the debt securities will represent direct, unsecured obligations of StemCells, Inc. and
will rank equally with all of our other unsecured indebtedness.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following statements relating to the debt securities and the indenture are summaries,
qualified in their entirety to the detailed provisions of the indenture.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>General</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue the debt securities in one or more series with the same or various maturities, at
par, at a premium, or at a discount. We will describe the particular terms of each series of debt
securities in a prospectus supplement relating to that series, which we will file with the SEC.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The prospectus supplement will set forth, to the extent required, the following terms of the
debt securities in respect of which the prospectus supplement is delivered:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the title of the series;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the aggregate principal amount;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the issue price or prices, expressed as a percentage of the aggregate principal amount
of the debt securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any limit on the aggregate principal amount;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the date or dates on which principal is payable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the interest rate or rates (which may be fixed or variable) or, if applicable, the
method used to determine such rate or rates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the date or dates from which interest, if any, will be payable and any regular record
date for the interest payable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the place or places where principal and, if applicable, premium and interest, is
payable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the terms and conditions upon which we may, or the holders may require us to, redeem or
repurchase the debt securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the denominations in which such debt securities may be issuable, if other than
denominations of $1,000 or any integral multiple of that number;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether the debt securities are to be issuable in the form of certificated debt
securities (as described below) or global debt securities (as described below);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the portion of principal amount that will be payable upon declaration of acceleration of
the maturity date if other than the principal amount of the debt securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the currency of denomination;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the designation of the currency, currencies or currency units in which payment of
principal and, if applicable, premium and interest, will be made;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if payments of principal and, if applicable, premium or interest, on the debt securities
are to be made in one or more currencies or currency units other than the currency of
denomination, the manner in which the exchange rate with respect to such payments will be
determined;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if amounts of principal and, if applicable, premium and interest may be determined by
reference to an index based on a currency or currencies or by reference to a commodity,
commodity index, stock exchange index or financial index, then the manner in which such
amounts will be determined;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the provisions, if any, relating to any collateral provided for such debt securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any addition to or change in the covenants and/or the acceleration provisions described
in this prospectus or in the indenture;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any events of default, if not otherwise described below under &#147;Events of Default&#148;;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the terms and conditions, if any, for conversion into or exchange for shares of common
stock or preferred stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any depositaries, interest rate calculation agents, exchange rate calculation agents or
other agents; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the terms and conditions, if any, upon which the debt securities shall be subordinated
in right of payment to other indebtedness of StemCells, Inc.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue discount debt securities that provide for an amount less than the stated
principal amount to be due and payable upon acceleration of the maturity of such debt securities in
accordance with the terms of the indenture. We may also issue debt securities in bearer form, with
or without coupons. If we issue discount debt securities or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">debt securities in bearer form, we will describe material U.S. federal income tax considerations
and other material special considerations which apply to these debt securities in the applicable
prospectus supplement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue debt securities denominated in or payable in a foreign currency or currencies or
a foreign currency unit or units. If we do, we will describe the restrictions, elections, and
general tax considerations relating to the debt securities and the foreign currency or currencies
or foreign currency unit or units in the applicable prospectus supplement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Exchange and/or Conversion Rights</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue debt securities which can be exchanged for or converted into shares of common
stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the
prospectus supplement relating to these debt securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Transfer and Exchange</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue debt securities that will be represented by either:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;book-entry securities,&#148; which means that there will be one or more global securities
registered in the name of a depositary or a nominee of a depositary; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;certificated securities,&#148; which means that they will be represented by a certificate
issued in definitive registered form.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will specify in the prospectus supplement applicable to a particular offering whether the
debt securities offered will be book-entry or certificated securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Certificated Debt Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you hold certificated debt securities, you may transfer or exchange such debt securities at
the trustee&#146;s office or at the paying agent&#146;s office or agency in accordance with the terms of the
indenture. You will not be charged a service charge for any transfer or exchange of certificated
debt securities but may be required to pay an amount sufficient to cover any tax or other
governmental charge payable in connection with such transfer or exchange.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may effect the transfer of certificated debt securities and of the right to receive the
principal of, premium, and/or interest, if any, on the certificated debt securities only by
surrendering the certificate representing the certificated debt securities and having us or the
trustee issue a new certificate to the new holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Global Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we decide to issue debt securities in the form of one or more global securities, then we
will register the global securities in the name of the depositary for the global securities or the
nominee of the depositary, and the global securities will be delivered by the trustee to the
depositary for credit to the accounts of the holders of beneficial interests in the debt
securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The prospectus supplement will describe the specific terms of the depositary arrangement for
debt securities of a series that are issued in global form. None of our company, the trustee, any
payment agent or the security registrar will have any responsibility or liability for any aspect of
the records relating to or payments made on account of beneficial ownership interests in a global
debt security or for maintaining, supervising or reviewing any records relating to these beneficial
ownership interests.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>No Protection in the Event of Change of Control</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture does not have any covenants or other provisions providing for a put or increased
interest or otherwise that would afford holders of debt securities additional protection in the
event of a recapitalization transaction, a change of control of StemCells, Inc., or a highly
leveraged transaction. If we offer any covenants or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provisions of this type with respect to any debt securities covered by this prospectus, we will
describe them in the applicable prospectus supplement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Covenants</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise indicated in this prospectus or a prospectus supplement, the debt securities
will not have the benefit of any covenants that limit or restrict our business or operations, the
pledging of our assets or the incurrence by us of indebtedness. We will describe in the applicable
prospectus supplement any material covenants in respect of a series of debt securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Consolidation, Merger and Sale of Assets</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreed in the indenture that we will not consolidate with or merge into any other
person or convey, transfer, sell or lease our properties and assets substantially as an entirety to
any person, unless:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the person formed by the consolidation or into or with which we are merged or the person
to which our properties and assets are conveyed, transferred, sold or leased, is a
corporation organized and existing under the laws of the U.S., any state or the District of
Columbia or a corporation or comparable legal entity organized under the laws of a foreign
jurisdiction and, if we are not the surviving person, the surviving person has expressly
assumed all of our obligations, including the payment of the principal of and, premium, if
any, and interest on the debt securities and the performance of the other covenants under
the indenture; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>immediately before and immediately after giving effect to the transaction, no event of
default, and no event which, after notice or lapse of time or both, would become an event
of default, has occurred and is continuing under the indenture.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Events of Default</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise specified in the applicable prospectus supplement, the following events will
be events of default under the indenture with respect to debt securities of any series:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we fail to pay any principal or premium, if any, when it becomes due;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we fail to pay any interest within 30&nbsp;days after it becomes due;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we fail to comply with any other covenant in the debt securities or the indenture for 60
days after written notice specifying the failure from the trustee or the holders of not
less than 25% in aggregate principal amount of the outstanding debt securities of that
series; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>certain events involving bankruptcy, insolvency or reorganization of StemCells, Inc. or
any of our significant subsidiaries.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trustee may withhold notice to the holders of the debt securities of any series of any
default, except in payment of principal of or premium, if any, or interest on the debt securities
of a series, if the trustee considers it to be in the best interest of the holders of the debt
securities of that series to do so.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an event of default (other than an event of default resulting from certain events of
bankruptcy, insolvency or reorganization) occurs, and is continuing, then the trustee or the
holders of not less than 25% in aggregate principal amount of the outstanding debt securities of
any series may accelerate the maturity of the debt securities. If this happens, the entire
principal amount, plus the premium, if any, of all the outstanding debt securities of the affected
series plus accrued interest to the date of acceleration will be immediately due and payable. At
any time after the acceleration, but before a judgment or decree based on such acceleration is
obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding
debt securities of such series may rescind and annul such acceleration if:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all events of default (other than nonpayment of accelerated principal, premium or
interest) have been cured or waived;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all lawful interest on overdue interest and overdue principal has been paid; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rescission would not conflict with any judgment or decree.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, if the acceleration occurs at any time when we have outstanding indebtedness
which is senior to the debt securities, the payment of the principal amount of outstanding debt
securities may be subordinated in right of payment to the prior payment of any amounts due under
the senior indebtedness, in which case the holders of debt securities will be entitled to payment
under the terms prescribed in the instruments evidencing the senior indebtedness and the indenture.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an event of default resulting from certain events of bankruptcy, insolvency or
reorganization occurs, the principal, premium and interest amount with respect to all of the debt
securities of any series will be due and payable immediately without any declaration or other act
on the part of the trustee or the holders of the debt securities of that series.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of a majority in principal amount of the outstanding debt securities of a series
will have the right to waive any existing default or compliance with any provision of the indenture
or the debt securities of that series and to direct the time, method and place of conducting any
proceeding for any remedy available to the trustee, subject to certain limitations specified in the
indenture.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No holder of any debt security of a series will have any right to institute any proceeding
with respect to the indenture or for any remedy under the indenture, unless:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the holder gives to the trustee written notice of a continuing event of default;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the holders of at least 25% in aggregate principal amount of the outstanding debt
securities of the affected series make a written request and offer reasonable indemnity to
the trustee to institute a proceeding as trustee;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the trustee fails to institute a proceeding within 60&nbsp;days after such request; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the holders of a majority in aggregate principal amount of the outstanding debt
securities of the affected series do not give the trustee a direction inconsistent with
such request during such 60-day period.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These limitations do not, however, apply to a suit instituted for payment on debt securities
of any series on or after the due dates expressed in the debt securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Modification and Waiver</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we and the trustee may, without the consent of holders of the debt
securities of one or more series, amend the indenture or the debt securities of one or more series,
or supplement the indenture, for certain specified purposes, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to provide that the surviving entity following a change of control of StemCells, Inc.
permitted under the indenture will assume all of our obligations under the indenture and
debt securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to provide for certificated debt securities in addition to uncertificated debt
securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to comply with any requirements of the SEC under the Trust Indenture Act of 1939;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to cure any ambiguity, defect or inconsistency, or make any other change that does not
materially and adversely affect the rights of any holder; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to appoint a successor trustee under the indenture with respect to one or more series.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time we and the trustee may, with the consent of holders of at least a majority
in principal amount of the outstanding series of debt securities, amend or supplement the indenture
or the debt securities of such series, or waive compliance in a particular instance by us with any
provision of the indenture or the debt securities. We may not, however, without the consent of each
holder affected by such action, modify or supplement the indenture or the debt securities or waive
compliance with any provision of the indenture or the debt securities in order to:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reduce the amount of debt securities whose holders must consent to an amendment,
supplement, or waiver to the indenture or such debt security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reduce the rate of or change the time for payment of interest;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reduce the principal of or change the stated maturity of the debt securities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>make any debt security payable in money other than that stated in the debt security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>change the amount or time of any payment required or reduce the premium payable upon any
redemption, or change the time before which no such redemption may be made;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>waive a default in the payment of the principal of, premium, if any, or interest on the
debt securities or a redemption payment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>waive a redemption payment with respect to any debt securities or change any provision
with respect to redemption of debt securities; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take any other action otherwise prohibited by the indenture to be taken without the
consent of each holder affected by the action.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture permits us, at any time, to elect to discharge our obligations with respect to
one or more series of debt securities by following certain procedures described in the indenture.
These procedures will allow us either:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to defease and be discharged from any and all of our obligations with respect to any
debt securities except for the following obligations (which discharge is referred to as
&#147;legal defeasance&#148;):</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;to register the transfer or exchange of such debt securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;to replace temporary or mutilated, destroyed, lost or stolen debt securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;to compensate and indemnify the trustee; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;to maintain an office or agency in respect of the debt securities and to hold monies for
payment in trust; or
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to be released from our obligations with respect to the debt securities under certain
covenants contained in the indenture, as well as any additional covenants which may be
contained in the applicable supplemental indenture (which release is referred to as
&#147;covenant defeasance&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to exercise either defeasance option, we must deposit with the trustee or other
qualifying trustee, in trust for that purpose:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>money;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>U.S. Government Obligations (as described below) or Foreign Government Obligations (as
described below) which through the scheduled payment of principal and interest in
accordance with their terms will provide money; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a combination of money and/or U.S. Government Obligations and/or Foreign Government
Obligations sufficient in the written opinion of a nationally-recognized firm of
independent accountants to provide money;</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which in each case specified above, provides a sufficient amount to pay the principal of, premium,
if any, and interest, if any, on the debt securities of the series, on the scheduled due dates or
on a selected date of redemption in accordance with the terms of the indenture.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, defeasance may be effected only if, among other things:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the case of either legal or covenant defeasance, we deliver to the trustee an opinion
of counsel, as specified in the indenture, stating that as a result of the defeasance
neither the trust nor the trustee will be required to register as an investment company
under the Investment Company Act of 1940;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the case of legal defeasance, we deliver to the trustee an opinion of counsel stating
that we have received from, or there has been published by, the Internal Revenue Service a
ruling to the effect that, or there has been a change in any applicable federal income tax
law with the effect that (and the opinion shall confirm that), the holders of outstanding
debt securities will not recognize income, gain or loss for U.S. federal income tax
purposes solely as a result of such legal defeasance and will be subject to U.S. federal
income tax on the same amounts, in the same manner, including as a result of prepayment,
and at the same times as would have been the case if legal defeasance had not occurred;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the case of covenant defeasance, we deliver to the trustee an opinion of counsel to
the effect that the holders of the outstanding debt securities will not recognize income,
gain or loss for U.S. federal income tax purposes as a result of covenant defeasance and
will be subject to U.S. federal income tax on the same amounts, in the same manner and at
the same times as would have been the case if covenant defeasance had not occurred; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>certain other conditions described in the indenture are satisfied.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we fail to comply with our remaining obligations under the indenture and applicable
supplemental indenture after a covenant defeasance of the indenture and applicable supplemental
indenture, and the debt securities are declared due and payable because of the occurrence of any
undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign
Government Obligations on deposit with the trustee could be insufficient to pay amounts due under
the debt securities of the affected series at the time of acceleration. We will, however, remain
liable in respect of these payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term &#147;U.S. Government Obligations&#148; as used in the above discussion means securities which
are direct obligations of or non-callable obligations guaranteed by the United States of America
for the payment of which obligation or guarantee the full faith and credit of the United States of
America is pledged.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term &#147;Foreign Government Obligations&#148; as used in the above discussion means, with respect
to debt securities of any series that are denominated in a currency other than U.S. dollars (1)
direct obligations of the government that issued or caused to be issued such currency for the
payment of which obligations its full faith and credit is pledged or (2)&nbsp;obligations of a person
controlled or supervised by or acting as an agent or instrumentality of such government the timely
payment of which is unconditionally guaranteed as a full faith and credit obligation by that
government, which in either case under clauses (1)&nbsp;or (2), are not callable or redeemable at the
option of the issuer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Regarding the Trustee</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will identify the trustee with respect to any series of debt securities in the prospectus
supplement relating to the applicable debt securities. You should note that if the trustee becomes
a creditor of StemCells, Inc., the indenture and the Trust Indenture Act of 1939 limit the rights
of the trustee to obtain payment of claims in certain cases, or to realize on certain property
received in respect of any such claim, as security or otherwise. The trustee and its affiliates may
engage in, and will be permitted to continue to engage in, other transactions with us and our
affiliates. If, however, the trustee acquires any &#147;conflicting interest&#148; within the meaning of the
Trust Indenture Act of 1939, it must eliminate such conflict or resign.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of a majority in principal amount of the then outstanding debt securities of any
series may direct the time, method and place of conducting any proceeding for exercising any remedy
available to the trustee. If an event of default occurs and is continuing, the trustee, in the
exercise of its rights and powers, must use the degree of care and skill of a prudent person in the
conduct of his or her own affairs. Subject to that provision, the trustee will be under no
obligation to exercise any of its rights or powers under the indenture at the request of any of the
holders of the debt securities, unless they have offered to the trustee reasonable indemnity or
security.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="F60024161"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LEGAL MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the issuance of the securities offered hereby will be passed upon for us by
Ropes &#038; Gray LLP, Boston, Massachusetts. The validity of any securities will be passed upon for
any underwriters or agents by counsel that we will name in the applicable prospectus supplement.
</DIV>
<DIV align="left">
<A name="F60024162"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXPERTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements, and management&#146;s assessment of the effectiveness of
internal control over financial reporting, have been incorporated by reference herein and in the
registration statement in reliance upon the reports of Grant Thornton LLP, independent registered
public accountants upon the authority of said firm as experts in accounting and auditing.
</DIV>
<DIV align="left">
<A name="F60024163"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WHERE YOU CAN FIND MORE INFORMATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly reports and special reports, proxy statements, and other information
with the SEC. We make these documents publicly available, free of charge, on our website at
www.stemcellsinc.com as soon as reasonably practicable after filing such documents with the SEC.
You can read our SEC filings, including the registration statement, on the SEC&#146;s website at
http://www.sec.gov. You also may read and copy any document we file with the SEC at its public
reference facility at:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Public Reference Room<BR>
100 F Street N.E.<BR>
Washington, DC 20549.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please call the SEC at 1-800-732-0330 for further information on the operation of the public
reference facilities.
</DIV>
<DIV align="left">
<A name="F60024164"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement on Form S-3 filed by us with the SEC. This
prospectus does not contain all of the information set forth in the registration statement, certain
parts of which are omitted in accordance with the rules and regulations of the SEC. Statements
contained in this prospectus as to the contents of any contract or other document referred to are
not necessarily complete and in each instance reference is made to the copy of that contract or
other document filed as an exhibit to the registration statement. For further information about us
and the securities offered by this prospectus, we refer you to the registration statement and its
exhibits and schedules which may be obtained as described herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to &#147;incorporate by reference&#148; the information contained in documents that we
file with them, which means that we can disclose important information to you by referring you to
those documents. The information incorporated by reference is considered to be part of this
prospectus, and information in documents that we file later with the SEC will automatically update
and supersede information in this prospectus. We incorporate by reference the documents listed
below into this prospectus, and any future filings made by us with the SEC under Section&nbsp;13(a),
13(c), 14 or 15(d) of the Exchange Act until the offering of all of the securities by this
prospectus is completed, including all filings made after the date of this initial registration
statement and prior to its effectiveness. We hereby incorporate by reference the following
documents (File No.&nbsp;000-19871):
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Annual Report on Form 10-K for the year ended December&nbsp;31, 2009 (File No.&nbsp;000-19871);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, 2010, June&nbsp;30, 2010
and September&nbsp;30, 2010 (File No.&nbsp;000-19871);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Current Reports on Form 8-K filed on February&nbsp;11, 2010, May&nbsp;7, 2010, June&nbsp;7, 2010,
June&nbsp;9, 2010, June&nbsp;30, 2010, August&nbsp;10, 2010, August&nbsp;13, 2010, August&nbsp;19, 2010, September
21, 2010, October&nbsp;7, 2010, and October 28, 2010 (File No.&nbsp;000-19871);</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Definitive Proxy Statement on Schedule&nbsp;14A filed on April&nbsp;13, 2010; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The description of our common stock contained in our registration statements
on Form 8-A filed August&nbsp;3, 1998, under the Exchange Act, including any amendment or
report filed for the purpose of updating such description.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will provide each person to whom a prospectus is delivered a copy of all of the information
that has been incorporated by reference in this prospectus but not delivered with the prospectus.
You may obtain copies of these filings, at no cost, through the &#147;Investor Relations&#148; section of our
website (<U>www.stemcellsinc.com</U>), and you may request copies at no cost, by writing or telephoning us
at the following address:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">StemCells, Inc.<BR>
3155 Porter Drive<BR>
Palo Alto, Ca 94304<BR>
Attention: Investor Relations<BR>
Phone: (650)&nbsp;475-3100<BR>
email: irpr@stemcellsinc.com
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information contained on our website is not a part of this prospectus.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>$100,000,000</B>
</DIV>


<DIV align="center" style="font-size: 18pt; margin-top: 6pt"><B>StemCells, Inc.</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 6pt"><B>Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Debt Securities</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 6pt"><B>PROSPECTUS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">November
16, 2010
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have not authorized any dealer, salesperson or other person to give any information or represent
anything not contained in this prospectus. You must not rely on any unauthorized information. If
anyone provides you with different or inconsistent information, you should not rely on it. This
prospectus does not offer to sell any shares in any jurisdiction where it is unlawful. Neither the
delivery of this prospectus, nor any sale made hereunder, shall create any implication that the
information in this prospectus is correct after the date hereof.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F60024tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROSPECTUS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>$30,000,000</B>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;</DIV>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f60024b5f6002401.gif" alt="(STEM CELLS)">
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">October&nbsp;28, 2011
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f60024b5f6002402.gif" alt="(STEM CELLS)">
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>f60024b5f6002401.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f60024b5f6002401.gif
M1TE&.#EA^@!+`.8``*K6<OW^^;;:A6ZZ(E@WB/7ZY\6WTXAMIW&(K6E*E;:F
MR6]1FBP#>_O]]-;KM`XA>'&Z*.GCZVI\I;S%UJ20O-7<Y.KTUL+(V>+:Y]?C
MZXC%1-S1W<"QTI7)6/;Q](6;MC=+B5!CE]'%VI2DQ'BZ,D)5B^/SRK.ZSNSR
M];"=PA,H>/W^_/KX^?W^_N?M\`X?>*>TR?[]_/7Y^=SKP9*<PV5RH9:DN/+L
M\MG-XL;FFO'W^9_.9UQQGJ2MQ9N%M?O\^R4Y?/#XWM'EL<[IH_G\_#D2?GB_
M+\;0V<C=I;&@O<[7X)K07*NYT?O]^;W?D/SZ^D,?@8.]1(+#/_GV^3`*>XB7
MJ_C\[]_NQ\N^TQTP?/W[_&Z[("P_@?S]_7Z^.>[I[[VLRY'-3/[]_1(E;_?U
M]_?Z_-SNNXZ<NPT@<2P'<XS$3.7PT'I<GO[^_?[__O_^_O___?[___[^^_[_
M_?___/_^_?[__/[^___^_!\O<N#RPWV,JX".MO[^_O___O___R'Y!```````
M+`````#Z`$L```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U+1W=W]^<'-^VG[9<'!]?6]Q?GU=;7YM<-IUW6YN?FYB?W'W<7]]
M;6YQ_6XM6KAIT\?-N&S=WKQ!V.U;M8>*^@B,9[!/-WOQQI4[)\8BNX0K"LZA
MTZ++'XINWO19@=).FS9V5K`\.&]<&X;?'$+<2<@/G3GWSG4Q5U.BQ3C7[ECT
M,V>.FS]$NCCTIHV.'Y4CX=3!4V?0/7D-)<I\VI.G64$'%6IMLR*`E0(%_X(4
ML-)`3IN`;7Y*C&,G!IYO<0(T>`MW;@,[&<<%[#-'3H/!A@.L8-MNT)RS9ON(
M>?FF09`A`#JHD>+%BQ0U'0`,"5(7CYR0;>2($1/@<V@-44I'0:TZ2(!Q73R#
M[D!\"0`!.1SH*5`7CB"=F!^^:2.F`)(=7B`,V,)]RX#OWB%X6>*D0)?9KZUC
MU^Z]^_?OXG<@L>!DB9?W1J2$,0[`20XS)A30!%G/7'21(5_I=&`V3T'W7$[]
M("3A@H.`Y<<]B?CCX"$4&M)0-VU8X4`')+SW'@0H:@=>>!T,844,(I*XW8P#
MI*@BC21HH*)W`QBAP7['^:=<$%;<M-"$D7384_].&XJRU1MVV('3-^BLD-`;
M=#CW%!TKQ&'5A]HX1T<7+83C'!QTQ#%./`VYT44,6Y%Y4R$*H4.0/![.@V8\
MB,SA4EL6`+!CC5+L(``20@B!A```:&#$>][M,(.@6Z!(J*&(*BK`#H[2R%V/
MA3HAQ`Q77#&#`PZ8H8<%!0204SC=6-5(3G18]<Z!L8K93I.?:/3&KFAF>54,
M!-F!ATH6I<G-&QM>1(<;=1#T#1TJM6"1F6B^T5$;=="!AR%O1-O%.)/E.8X?
MUFX(Y1SH6*#!IP-X`8`95L!V[#AU-$"?%#<.:L0.],XT6SE]-+&&`%+,*.\5
M#<S6ADK,VB&'%4$0:>7_'VA*Z,BN5<GZX9=,\NJ)1MWV$8="\\@#QPH"A2O1
MGOD<6<A%\>!!639UU%$9/D'!P>9!A;@Q!T'/QN8A'7<Q98=S=.X3@!GW?4>"
M`!9T,1-,ZE@K6Q\!%"!$%-UY-[4%3;S$$DH#$;1"`3E$X81O?>"QSSCDV"33
M"NF\ZE-ELWHC"+!\=U,9WZ0H5.M=<=1A,F-L$221.G98/4X^''9C[5WCZE-2
M"^Q0U%1"L>&-(.=SPX3@9(J_M*%D`5QQGW=JF-'`"G;5L=E+==]CK1A=!*JB
M&C,TP+D<^YSCJQ@Q`-1"$\R]]D.7+PE2#H9>H64.'"]1OL@W<-AA4T&<C4,\
M_TTB=Z+02^G($4``+%0PP0D35$#&;-C0$0#G;5P/ICMOW!%26WDA5P#LPH^&
M=`DX`8B!(59"G7%LQA`EB0&Q-K.A\UB@`^_I`-G2P0]T?$$$'`"#`39`AM?8
MI`56$%0'3$";EQ"O!7[XP1<B\(7Y=61N4(J!%F1RA[SLKR&$D,/2;"(E1@B+
M(,B+@`@,@(4->&!NQ=/&*>*PNS9T(0-[R,(#'H"&%SP@"SPX0A?@$`<BV.`#
M:$RC&M>(1AO(@"V::0,*F(``"=CQCGA4@DD*4088E*`$9]#!"HC@(1DP(00@
MJ`(*9#:(-A1@!]O9P@[,$YOS>``,!&"`)C=9A`/@@/\%`]S,$V80A#;@00PV
M(\(74K``*FPR#02@``:>0+"7/"$%!\@E#O`QB`WU80H^R.4!(N`(/^3L!@K(
MY"89D(8$<.`)DVD'TPKWAGC(@0A,R,,+O+C%;7(1`3_`0Q=D``0NOJ"+7$3#
M%KMY3G7F00=XT4(%0(`&=3[`F^E4YPG($0^4'4&+7+2!!`TTCSE,(`]<?$`/
M"G(/<OPA!CDH4;R"H`65M($%!E#F,I=)A05@0`QR(!,Z!!*2+_B@"!M=9A%$
M(+>[L8`-FBP"![+!#27]H0T>4&81-M`(K@4``QI-:0)`"26;AB(A,-"B%^LY
MAGJB(0LG:$,,^D#.>R;TJOC_W*([=5#-/F0`!%FU)SL?<`)K1<DF/5CG"W@0
MSLKX!"`(0.<#^&`UI3C4"FJ`CP,ZB-,#H#2E*86"`@B2ES_003,<"&I*TW``
M%JC#(2^-Z4P;D=.8\I01+[E!4-/`V31HT@><04SY.*&0?OR`GO<LP0B.H(0C
MP$`"/$!!#"93ACW@T8XEL"H(;BL!!,C@#F.R`3J?RH7B&M>X$QC'6<VQ!V^B
M@0M'Z,/?A/8'%-"3FSP@@LE2HA`AJ&@'#7!*&V[02DX2X``44``%#D``5\84
M"_MPCA^TD`(H;)(*Y_4!!8))``)\00X$^D-D&2!31U26P)==Q#X.P$D?-!$'
M'/`!_P%$((<L?<D4X1*:$M8YAB/\X"5L(8,+'/82&9B8!2PP\1FLZEL3N_B-
M=["##"1@U1(PH0(9J`".,\#C#.C`('-P3CY"L,X'C.$#+1`$TF!X!!58]04E
M0`$X&H+!'NEAJGUX@@_<RP`"I.`+3^B#2U@0`0K8MZ,8V$=-16!?34+!!QB8
MPKC$0&8<$.M6WQAP@2FKTP0KH@U/:#,5*/`$W+7A!Q&8@AQ\(JM3S`,/-M`J
M%XB`N\BQS'#0&@E!WM"".="`Q7T(1^*<XA0WZ(`'ZV1"$VQV![NTX%G[:-`W
M``*"(J,A!"P0!T&L%M<B<T$))[%#-:WPJ"UTP`J+V\!?N_\<`1`'&6E2Q0$!
M?'"#=PC-#F30*!1$4-&&-"5:X[!*K00,4P)/EA$'WFDCYG"#34(A`G4P"$R$
M_0[#`K$4]T!3%>Z)AG?*P2DM()8\E%*/E,6A>W[XM!<1@#'Y7@A/I]ZB"B[P
M$G;E#"RUFF:ULE#/=>:A`@0<APRX\.0'J(`)U82#2F;`'0@XX7YSB,$"-NG?
M^UE$(2B;0P#(\`,Y9`,/;J`#&#@I`H+D*582TO.Y%Y%N/R>B#U_@)`Y4(L1[
M,V2:I-!&"XX@5CZ@0')WZ8,<7H@1A?QA:)_^9D'<$(X^*$X>$7_!Q-=N-CIH
M[M6#X'0$UDER+GZ`92#F^A:!X,W_,ZAD,G)P@G>\H(=]O$$$GF4`%+#@O9?$
M`PXVBX>E'[L.%B1`DX-.WF-[&;@L"4+I!NYS3UFP;`)\E"!HDJ9;1\N)<*S@
M";7VH@I"T`,7?)@@UI+(<^JP$("D'0T,'T?;HZ6.N*M@`L0*.-Y*PJR".$0E
M:?7B&<KY`!`083)6K($ZL_"!=4K@\%V0PPY@%P2WO\$'FSP`&>HF$FU$Z21.
MP5@WYH"!-KL>P`_C$""F($R#>GQF68V0%PQ&<W#&`M,A-R[!=K2W"=JP#W+0
M`P"E>X"4`<^S)MI#"'&0=B_`<(D0<5N$`".0@BJ8@F2`+G@B"'$@`>HT<43V
M`F.0`2"F_P-`T$4@4`%.]@`A4"V<$P;>T0$-X!-/4&X,H`!B,('V=@X&X%X)
MH`!@4(566(5IA@@&B&ZJQPA<`U0<=5XBP`+;L@)WL"NFT`UW,!!$D%16I55`
M,`(H0#QV<0@AV$TDB`@FR$U.Y51YX`(7PA!/D5M?E`$PH`+G1`,/TP='P&(Z
M@%`/P`5`UP9WX`?O,@#@Y1,>\'F:A`-]@`V-(%]OH`"1QTR<98J>E084P$B$
ML(5,UX6+H'-OL`$$$'F11P7#%`-R<`?FX`9%E(8!@#X9$`(JT(=>%%MV$`![
M5`AW>$]Y>`@F6&1J]44NT`\7$A9]!P0Z,');5`(RT`=$@`!>E/\%%T`$)3"#
M3^`GX?(N6P``3>`3-\")18`!<](WVI`"@+51JA@`6EAN>\:%",@(;N`JXW52
M@;4!C"$/OF@*="`'+2`'R3,T3U`!']!W]E0#6O`:=BB"SV@(T=AQYZ156>`"
M*V`'>N(S9)`%7E0"1"`'-(8&*E`!?>`"7.!%(8`"*]!<6W0$L5%-8;`=._".
M<!"/H(<#^?,(88*/^0AZ:>`#/G<(KJ@(3><(04<'L_$%F+11!!`!HF54(\,6
MXY)O["(&*-`#?2=W2J"1",*1BF""*K!:1Q"7<GD$6A`E\,`-/GB,0W$"/W@&
M1'`"8Q!09#(!]E0%*X`R2\`=2V`%W)#_A)L$!DTX*SC3!P80>0F0`DF`F4FP
MF9NY`1_8BOZX=%()BXH`*_9G%UJ`!0M@BZ`%%J>@%'10!RU@#B[!%NJ3`3^(
M!F<@&1N)AVV):B9W`;_Q$G"00'0C760D#X2I?2LP!RY0`BOI`C0F=SCH58'Y
M`#S`3WX@`-RA!@7`$F(`?YIT`%.`=8D@.%?1?YJTE5@2#AB#-";3CY*5>@')
M"+!B-I5'7INT`%I@=5G7#G4P%`#Q$GC1!2&P5'2E0&OIFQ[2#Z>F>Q=@-7+@
M#RU`?!)A+1/A!^5G9!.0?EW`!Q+7`[7V`"RY#R@P!EX$`K6Y`D+`'8P7C&*`
M`Y$W>=+")A?A_Q(J81!L]P9RX'F@1P&;\8LX=R3AT@UV,`=*IR"Y8@]+T73M
MD`_[!Q:(@7-_H!0&,9QR``:11P"MYI^BH`VQ\9"-\6\$V@(A8$]\(`8KT)O.
M>`CQ$`=N&:%=(#0#(0?381=B`$,`063]A@(/R8B(&(F(B`9,(!!V0`0U^44_
M8!,6\!XOIZ9/,'/K^05S`Q;[X#ADR!BU60<*X&X4!A.!:$PZ$P#'T@[QD*2:
M*FP?LB9NT'3=`*4U85$%(782HUP$03Q#ITD)T!%^4PKADGXK<`$N\"8E845*
M`%!H<`)QL*8+VJ:&,*`/>DYG(`,_,%MXTP5D0CLF(PY5U7TRH*TZ</^.W/0"
M?\@/;$%D)A<!:](`KW-L>#`9.+!L"8`!&7D9QM,'6B`"L70#=F$3!]9E!J`%
M#*4RKJ$Z5B$T`T8%/D"&N$-\YT-8=7!@5)`$%65*7*$1:AH;L8$%$5!H%A@`
M7Z"$!W`NA#,*N#.30!`"-G`!/%8!,`!6Y\0%+L`6O;E-'?DW(3%CWL0%?-`#
M/ONS/QL!278.$:"2+Q`"1!``<*"F9Z!.ZG2TE,8Y+8``ZW0$[&(0`+`=1G`%
M=A%S!U"*!``&7Q`#W5`'6K!*]E4$;-!LMHH%RP8%*1`!%:4M6G`#&*"+;,<5
M%R6>DN<#"O"W@`NXS380++"`DI=>@1NX-P#_8C'07SXP0A&``0;`!I%7!&`@
M=B4["HO1!Y&F>T``!,AJ<C9`-VPZ@APBFRT``U<EC=VT15$E"'=P!"B*!A+P
MD.<P!QEPG?54J&'G!DSPM##`+NI@`=_5`#$P-!X@J:!W7BG``;@45%2`!7:Q
M#3&7`LM&!5#`!A20`NO57_R:MRI1!UBPE,N4!@KP%R^AI>0+>AM0)U_@7E10
M!%``!5S&`/(7&)DK"M-!$,#)36KU5'ZY#\S*C`IGNAS2&#I0`_Z[P&]X`CZG
M%##016@P`FMR!R4!LT_E`ISF.!D@P0C`0'X0`.M7(T(0C/O@`0=0OTL)!6!`
MML(B#D^06.3+6+2D_PT$1`9*N)14H`"+]A*;6(KY2`4;H+>YFH]IP`:+FQ?Y
M&PHE(9L5(`$@\(/K!`024`$]1QWUT*P/@`"L*#TE&0,ZL`?<=U5B158L(1-\
MT$5C,`%W`7Q],`).RP/IX(O:\H@IND/JL`)0PQU&L`9CQSDL(,,ZS`9W.Z$V
MH6M=8%)M!EA0,'7:@`<VTP9DX`-0`,0;M</^X#0HO,B`)<3MT`<W0`$$L&PQ
MY4R@)"U689ZAH!%*T04HH`0GX+,PP+*+RAAS8';/ZK(PT`-*\)G24Q`J0009
M\#XG4,S&;,PND,E]`,O%C`)K\HDS:<P9,!'B@`[$/`&U',)6X`00P!T=L/\&
M`^(28K!*"P`%14`%Z(Q?!X`%4]`&)FP%0K`&)DP03X`!%,`&HUP$\IL`/B`"
M)11'CB,&6B"Y'%#0!GW0$>`/U<0N]6P`!_W0''`#?!('8D`&&X`%"I`""C!"
M[<P.!<$0K6#!V&HMW,`(?A`3)3$N`?9TGQ@0+OW2UC</%KRYTH46BA%\#6(0
M2N'2E0@B*Q`$D%0C*T0[L"$&'H`#!I"9"H`%<::+D]$U`D`"*S1;CF-%'H`!
M."`".(`!-Z`%(,86Q"(3-8&M>',WY(`LY@"":C*D5*H/:\(D)P,QY."EKY`R
M\+#$,V,S&K$-L^(S4^(0'`,F#45Z!O$A"&$0_O#_IF%!$.[R'E[@``W0!D-#
M+%\=`QTA,7>Q`A?$(UX0/),Q';3CSF,'1^C#/$U`-T&!<S7](1W$C'\-)D.C
M#H(0(;_2%'CM"F"RTHH`,;ALCW\-JS_$I+T$#X;]0]#!?&W0V-M!`@!@`@W@
M*P(D$P3A&4X@42<"`&M0%[%QUCAG3&)`W5%`-<_]*^@)#VX`&^E0T]53.>9M
M$<-]TDU1TK=`U]MCV))@W^>)E&!B"(KC0$'0`3="`DLP!,QA+4N[&6ZA!P#P
M.O#!'@,@X`0>V>=0+,QC!@#`+U*S`P[0*I+M,XRS-A53)$UBW"+CI5X9#/M3
MUTJZ(14JO"T0!-7-(S7B_P6I(0!.X`2,PBG6W2,"8`).X`7N`0%18!PVCN,`
MP"GL$3:$8AQ.,`1"@"I0OBH%L&CLO=^*T"$GK@H+DN5+@M]7KB3%[>5'%S)=
MSMH@)MT-,`,[\"B04B,ILB+?\2^0W08-<`5K#AXF\N9XWB.=$DF@`B0VGAQZ
M0"2R/>;V;>5=_B#180O:\`::+0!J8`0W8B(U8@1J@-UJ0@@Q<#"1/NDR#@&6
M+@!K$`-7``"=_N=$WN0SP"K,ZH2+G@Q7LAF>X0!.``!+<.M$[@!D,U6?V01R
M@`>S7NNXSN0.$`2G+0^6K2\.P"@`<!S)80)$T@0FJ3&O#A'KH*9D>Q*Q,=I5
MC<08GVG9Q_GADS$'+;48<$!`N*.F3;%ITT$]7%[ML+XK*R$3:C$T(:$0%YLY
MA3`3&B$XW5,G`IP_6F$X66+;ICD5[P[OL/XAYQ--\K9=X0!'AL"+5/H5%*$F
M!91Q&.+O)$[?"C\-GL-=@F-ZC+8A,K$K``$N"[$Y*:X2^-`",B'?S_'QTG!O
ML:?RDL!('&]V>\,T'M]+=D?S0C_T1%_T1G_T2)_T2K_T3-_T3O_T4!_U4C_U
45%_U5G_U6)_U6K_U7-_U@A`(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>f60024b5f6002402.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f60024b5f6002402.gif
M1TE&.#EASP`Y`.8``#,M+;BZQOKZ^>OLZTE+>Q@75_S\^\K+U>/DX@\,#7=X
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M3NCIZHZ/J!P8&::HND!!=`L,3_O[^JVPON_NZW!QE$8_/OW]_!$35^_P\%U>
MB.;GYQH;72XO:1,249Z@L\7'T.WN[GQ^G/?W]?+S\QX>6@T,3/3T]"$B8@\/
M4;*RPQX?7B@B(_W^_O/S\/?W^*6GMH&`HGUYA_[__PH(2/___R'Y!```````
M+`````#/`#D```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4AWU"F$(0&P$4GI\4
M`4\"F4)]?6$]=*!=&P)]?T)N!TN?2P=YL'T3&ZN>2T%!M:#$Q"H?0EQ6%@%T
M2W0!0VZFIV%C0<6@SVI*$YB70I7BA$)AF`8.`</:04]N!D:EII.H!@LY8P$T
M&&]U;__],'P9`F&!@3`(UU3@!U!"A368PFS((*'?FQT9>IB[L^;&F7YU)!`@
ML`-DG9,H4Y[,J"0`D088SF`@HT`/`H3F)AP@`!!DSY!:V*B0@M!`N''B4.7@
M`L7!OI(]+YK(D,6"C(,XCT92.J''%2T%_(@=*Q;.FPQ1H!A8FR,(@3ED__UD
MQ)0CB@DX9,_HR1/&@!(%6\86T'(FKN&X&;K0,/%FCIB@+M0\^;``YX0A#<(>
M'KO%#($E$`QP"8,T:1@!$*)D,+/9#YP"9QJDL9KCH%9(2LM4.`.WM1\)1(C:
M^W!EAV$M%C!!"2`A;H$,`_KVH$%V<'/?<0DT,!-X2P,7#@9,:9.C<CDN`UR0
M,8X=S1<I7'*0+DVISQT!"+ZPQ@Y'C`D%Q\AWVR.HR$#'761M@49O8\VAQ2CW
M6-``@V/M<`!",NC!WEAPG!%%>4^009896NR'W5AUH"'6'`0$L`84'VPPQ`$'
M6("`##E,8(4:;%SG&QE6Q#<??9*@LD86<IS(H?\<9&1AA7QAW($)@9>]E=<7
M5^R1&5D[T#'%`AWY2-8<08PVQA5O&(;&%6/DH`(!9,G1P!DH:5;=26^HR)D)
M6<C`RQ4TD-%``V1\D44/%EA0QA,5F*`%#6RP088$@8W50!EK#4BD(WW$X9:2
M9+VF104(3&">IHGT@0!U9)G0Q9<0'-``66@08<44`6A1J1^[^I'&&&$H08:>
M<6FA`A=ZF-"@%EG,2.,-&_*Z!XTJ-$"L&3=8<4\95XB)!@%I+$9#$%+0*$4.
M`I3!@(E^D#&`/4-N2J`#7X!ZV!M?6%";.8]PH8*R8XG!Q@#E"?`7@VBP448/
M>]@I$UE$*&%`#UI0.);_&14,T.U8:#00A0%WG,9<=4L@I(86>(EUQ@%J&:!3
M!J&>H0#*!300@!0XAI%#&VDDN:("[_`K+R1AJ*"%O?<RH$1MJ!9R2A]G;@@'
M!D'L:T`<*C!`!!%L,!#$`+E6^MRL8V7P1!@6G)%R7'!XK(");]#@0)1W3)%$
MFF.=$<`]7]@Y!QD]K*4S`E>$RB0&8J&A!1UK&#2!&AF(,98$-XPF]-"*G*)<
M%F(B/?D5E"%$#2(AIV(MQV24(65$<5AA11E**#$&PW6,I84+&:RMQ0%"J.#S
M87)<,6&%"M]QBA(,V.G'[GX='3`#T85L0!EI,`A''5K\#H<65_2@1!8\<4S#
M_Q.E8+X(.$(0A[?G<5$=&A<@PW((3A9@L'8!"KQBB'T(Y1&V6%N@@1*^P*`Z
M!"`,75#>'!BT!2V(20*@D]\3OB`Y2VDD"(5!D0NF8)2^6.$&NX*#&210P;)(
M8`]#Z$(&_?"<`PC`?)PRAQ#6P`;E@6H.(=E/V]0P@;48!1%A6``7U!"M.E0@
M#/(C1U^XT(.WY>T&$-@#L?R0!2Y4@%@-'!;'UN8'#.AA`O*35:\R<)4;K,\/
M9PA"&[`2!@0P(%1FD$.O7+,#&D2!",:!`P&"$(>FP=!I.%$"#6SHFYI5(#(!
ML)(?YM"`(<#OA_-;P`0"$"T)N.!R@SC/)'5E*37DX/\*RJO`!VBP-C%\(0F$
MM%T`#""_(#AO+%]82\/RHH(U]L4`$S3<[^)RABL$@0QP*<`>K.#'/PZB#P8H
MC[!2R9DZC,0,&,C"`"`P@1`A+&/P:UHYVD!)LDB@"VP<@PL:0``M:*$!;-"/
M^*+0!#21A0U*@-/%KA``0G6M`A5@P!<(4(<&J*`V!Z%#82J%L;ZPH81HK*4/
M!>!*6IE@A0!<X!PP<(,;F"`P)@A`,1D!CKZ8(PRCT44];),)72`D!\LTS!Q,
M\(4*T$$-%E##S)(@`X,X`)AYH<,$,$F(.QA``"J(EAF(@*,<?"`(#5C;&QJP
M@[7!80<8,($$N-@`-2#N8@3_J((3"",3#&B!#`RHP`LX$((91.`!5\`2&5AC
M@B`8%*$2H(,,X"<`C:T/#G*"Z!MN$`P7?"$#-U!`FO;*A:1(3P`RF,($N#`/
M5.!$<)GXPR4\V#?#;*\+/8C#`A8`A2>DH0L?X,("-H#319KA##<8`R0-H3,#
M#,%^'-)"%Y[PA"Y$KD%GX*22*'J=+4B@`2"X@!Y>N2(SF``,=L""<NW``1S4
M$RX-V`!"0$D64SI`!FVP0A<0))::?6&7$GA">62@!NT(;PMU2((!#&L`/#!!
M`QH0@3=,"@$;X&PTWY`L)HRP!B*<D6,$J,`3:GJ:-2``"IN=CAF@F8$*!*$;
M/!U$_Q#],D@XFK,.%'(FN[`S!QH89PLF:$`&2J6$&TC.#'8:*@M>`(`$8*$$
M#%`D=#9+A\Z9@0T!",`58#L6$]S@H!PR0>#"`(4AE"@#;'C#&>@0+TX]K1PR
MP,$)[`"`%:#`')>8P`-B,(((V$"&NLA$'-(0K;B\@0QJ-`)()P#0`?S8!4^P
M`36A,(`\&&]^()-!%B!:%BZRT`0$*&%_ZB"'0F.X6&'I)Z#7P(58G:&!U^E0
M``;@@1C`X`08D$!OYO"%FB[@"0#C3`%,@($"<+$`7OO"KCI6ABAYBE):4$!N
MW5JD3!@``C\`P@F0`(887/D<1>"`<EG@!2P+`GT34&$A_?_Y`0%PX=D'@<+K
MW#`!*$BA!RH@0A`@,(]"?",50/;-M[[K338D(0OH7HASYE```I3Z"^\0@!4B
MUP`$;6\(`\`!")#`![5=C`%K64`;BF-9/XM!`3V0%5G>H``IF,(-7:A=S4:B
MAB8W@G^W)@$(P,`"(/B@!G@PAP&:D`([).`$(HC?*?1[BCL<@+B'45P2>@"%
M?44D#&TH0P`J0!+%68"QJ6J#!3(@!S^[9@YR2@(1Q`"'IHNA`0=8PQBD((4-
M-&`+3<_Z'&+S!C-<X7T0N,%7[P('-)`A"A=X00D>D(:I9IUR![F'`U9C=`X]
M9PCDE:=8'#(%04@A":R!@PG(0(/_"Q7)IQ,X0@H`4((95*$*'H!?&""``S"X
M>`10,-[3G/8$F'%X5`ZPI?QPN9`\X44,64!&JDY3!CT00`)F$,,6Q'!:,K@`
M`0Y@@`EV'^(D,!HG'V"`%G@O50P,"M`!:(/C1$"$#!!@][%.`1A*P`0\U)/X
M:`YX&Q`0`*+770P80'@./#4I"9B_12_\PY$R+8'_5,#P6_'I`&)`Y15XO`7%
M%HT(=("%!"#A")JW>830!QTQ1YM1!VR``"$E"!/@`C#G!S30`W[D6"`U`&I0
M`43P!43@`@<`'SD@`TK@`"+H`#>R+R=E!1L@@K3U!#KP`E3@`)F%%08P`(O7
M`D/P!%0`_P14%@(_``&S,X(D.`4G%0%`\`(UP'.P)P:T)P'AIP*:56!/,`12
M>(-28`2"@!X6,(4=(#L6ERJ:@W,SD%S!!0;_]U%XH`$M!@`SP%A/DT3'!`'_
MHB0=XP"94@WB1"EY`7_&Y#288`,EH`%><!"#<!],<`(`@`,0@`(K8`=V``)`
M4`)%8!3R@SY"@`)5D`!V4`,0(`5!D`8,<`5)$``TQTI[>&P4.`$>``,)``,U
ML`)5$`'<E@PD4`()D`!`@`)`ERK30P1R2`;250Z;Y3CC9"=;X`)Y4(K>AA`/
M4`(>L%-W,`@&@`)`@`4P(`(B$`+)Q0$I<`(<T`'Q(PB9$`9>$/\#RA4"")!,
M4)`'$``!;0`%EK-11#)97-`&'H`$"0``(]`"P15R(+5__0<&#X!?F3-Y*E`[
M[>&+12$#`_`!;`8!]&*0?@`]R#B`"#$"MV@4U-`'>!`!`(`%(U`$+=!B=O`"
M55`"%Q`:6#99(#4#EO<"/[!365$..!%AYC-9`M`!_(<%+Q`#.XD"!V$`']`"
M/H")(=`$MC&0*.5YXH:0R:0$=*`":Y`C5I`$H981$WE,"($$*Q"+45(.'@`"
M"0`&$7`!)U"+5(:/-M!H7H`"H74'\]@$M`@`5)!Y-Q<1-^>&?W0)T<@")N<#
M.L`!0.`!`G`0$_`#9?EB1S`:=Y8JY;#_'!NF)DS)1`J0`4&P!D/`<W9"`$]P
ME:88!G]("D*`%>.87"/`!,)6BP"0FAHP`1/``S$``BMP8"C`!"'08C`P`TWP
M"FVXFWB9ET(P`1>@B@G@`U4`!+#H0TVP`OWG`RV`!VV8.8Z%`&10=X*1$46Q
M!@H@`1EP!610=&2!')PI67W!`2W0!I:!`BV0C2W``;5X<B$`!@#``@+0!/07
MEB30`1H``_UWCQS``^D7GOMS!R)PB:@Y`C]@2P8@`S/08EB@`RG7FXC@6&T0
M!,S471FA9D:5/(YQ&!A@`>$IDR$`!"(@`Q#@!:[9D0#``2>PGU@0`M@(`#4P
MGRMP`C`0FQVP_P(BN9,U@`(!N)NGP5@@E4V:(QHIR9LKUX9"(``]U!<3,)B8
M<`<?P'^H:8X"T`8R``504(^U2'T0@$0QA!`#<#J;\1P],`%C\`3C-$7MXZ&<
MF0D\@`0A@`,XH`$<D)H^X`,<8'FUZ`,:<(DG\``?@`(><`$XT`03T`&UF0`@
MX`%>,``V``7F`*E20F1-X`%'T*@_<`2&>@=W``$(\`-&.:E0``'.QH[&\PT&
M8`,>0`)%X`5%0`(>T`&C`0418'(GQP)-``$=0`(/P`-'@(W#J0$^Z:47AQ,"
M('8&:*$;L`%=\`4F@%"&T:'AJ3D0L`(E@`1Y"@!D2*/66HM8H)6IJ?\#'C"G
M-4`"H84'P8F))]D!%U`#3-`$3<`#>."6*$`"*P`".C`#-8"O%R`%`N`%3'"O
M&F`#+H,"/!`!1X``3,`#$"`EG5H$,X`$)3`",S`"'/`",^`G10`$J,D"CLH#
M(5`")_`"(V!Y#9J8^75QU"`$N;=+U4$&`2!\%3H6TLJ9X&``'<`"7#8"(9`"
M,&"$(6F6'*"B,<`$9&D''#=-$2!L6``"3;!_/@``)Z`#0*`#'=`&(C`"AGBG
M`#"4?.H%^%D%J8ER;7`$&@`"59`"?0H"'=`7*)!V*-JU_:>&4]`!Y'B/(P"O
M+%`%R45EMNH#L)B110(!0Y`!J;1U!"!'N\7_IE<9CJ<A`Q_P`3@``QP0`2(@
MG,/)`3KP``A``O9X<A'P`3SP`OUW`DR``"/0D68)!AK0N2#PCR'PN;:8J8MG
M!Y<&`+X:NR6`M"6`!3[`!%Q`<D,9EHOGK6Q;!"&PGSIP!")0GU@`!L5+E#*P
MFT7"!;@R/.P3%R;`N'NH.3+Y6#*PM"_`!""YGR>P`A'0`5#`!*\;K$W`!*2+
MB2O0!+&[C?VW=BBPC/T'`P\0`;08EDR@;\GU`BL``V`P`R&J`U6`!5V[BA[@
M`2-@JZ^XB%L:JZE;BU7`!!IG<EC``3/`ERX&`CS0`3(0)2NW%<FT!HFDINP3
M7<CXI$LD>:+1`=+'_P00<`%Z:@<L<&4YL+$<'`,=P`,ZZ&+]>0$ET`(/8'D`
M<`%MP`3_ZP,/X`4:P,$K@`/QRW$ZX`..J)4ZD%QW:@<CH'BV^J=PN:<X@`)3
M[*T7P`336(N5NW^U>`(XX`$L4`0"8,*UYE,RT`5:P,)(HP!6\,)]T00/\``=
M,)@&T`9+&P)@^P+>^@*EP@4(`*S4R`,0[`/+J0$1@`0CH'&U"`0=8`/QFXE>
M<`3_:Y)(T'\=K`,G4`(I4`(QT`*69P<GX`-@<`$XBIHU(,4</`(BP`+#FP`<
ML,%[>@%O.Y0`$`)'P`(&>L?$BAM#N@;C])@WE`9N\,(N@X8ZC`=K80,K%O_*
M(+R*3,":7E`#*WJ/&N`!(5#++F:<(Y#!%R"2,S`%#Z#*(/`!7I">+M8"*<"B
M-`H"(U`"*_``[7N651`"PXL%,=`$'3"\_`O,^^D#%P"L+I8"*/`#[8L$/,"^
M.PIFE5`.$P`V9#"SK8$!QR+(*/"_C+P6'<"S:,R@2!`!;8"U&L!KRL4!%Z`#
MV&IR)<`"(0`",R`"CLR<18`#_UL%).`%+-!BJRA][0D&.J`!]A<#/)#+PZD#
M,0`$2/##18"3R\EE-#JW+,"2JLP!1_`#)7=RO9K51<!8*3L)Y6`/4S`$1&`"
M%H,=E$-,@MP$JGC+76H`(@`$&E`#0TF-$<#-'=#_`IQ\B0"0`J\\`J0+QC&`
M!"V``DO=M!%@Q:2+!<(:`66)B2^`!/'+G!&P`DB@`SR0KO<8`CSPJC5@>3[`
M`RB0J-\*`C"`K\H%!`^`!'Q[CS50!#'`H"O@`8H-<C+4;7!=.E?C`(WBQX>!
M/P[@#=AL`UW\`@_0!#*`!Y[+:_<(`@^0W54-T`^@GR<`!!RP`D9,C5JM`Q>0
MKM2H=E5P`5A@NDO;GBFJ`7QI!T`PT4B@VQW0OHU=!.X(!0.JJ$S0`@N,B25P
MVP\PC;UFWB'YK3@PH\LY`Z8=`T6`1,]9'T\6!A.@!&E`!F=`TDL5``@P`/]I
M3*$I`#R@`]>J`R.0`ANG_ZT<4,<V$`&O"02_G8J^BP2M2P(+/'UE)7W(Y:VL
MZ`52R\KM&9:530(`8`=5,+0MP`--$(;WB.'.'(VI#`.\O0*S?`)4_=_S70(@
M@`-'H)^WC03V"P!(`*?RM9A$$M<3L`86D`3.:FIJ$GY!$`!!H`8?@(P>-0'Y
MNP(R_@)`D`+HBP!X@%@SH+8>8`,",-M5`-2XB`#6B@1UK,XC@`,A``,P``0X
MD)8Z``.8[*TX[05<@`(Q4`+:B`,#,`%ET`(T&@)V+(-M4`,<4`+LC9X_RP+J
MJZ!5`*=%(`,R0*<EL-]%@.M5P-X(<,=P3A_V\5-*^@$M`2CDY"@$0`8XA@!S
M/?\$%A`'@-Z588`'"'`$)`"K18`"*/E3':"I,`D%1_``)#"L6(L#[PH%-G`$
MP]X!<GH$H64`ZAS,2(`#7A`R`B`"_<[-XTX",_``(M"E(1,RP7M6/T"P_"[;
M.Q6-.!`!;<W29\4#-C`!"$#Q:;DZ$&I8M^1#4Z`$%J`"=)`%+A``!]`#4R``
M.3``4C`&A56*\A#7Z$)2I2`XWENE.Y4)J%'T(&44B=PR![&T^UD"YLH%X#"/
M;>#6C4FB=[RRY]`&$.#6B9SU6[]&MC:J66\`H^K6X'#RE4")I0!2>1`';N`&
MI(J1H2DZ`#J1R-0&.'":JX@#,'GW@!_X@L]1-A#<^AFKEAVPI,@]^(S?^%>I
M.32<HOII!QJ`$U*B]HZ?^9J/%.5P!R@``G9`V<D%Q-\@@)M_^J@O#J$Y`-,(
M`RS0NTCPDE.2^K1?^Y/`!:T?L8KZ`VJQ^+;_^\"_/T4`GS70Q3!P!$S_C,&_
M_,PO!$S@`R50!2<P`LU(-\_._-A/^T)0!$C@`S4J7T6*^=D__H,O!/!.!1Z`
:`LX,C^3?_H$O[N&PX>X__YE_PO2?^8$``#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
